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A B S T R A C T
Background
Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation and distortion of the smaller airways.
Bacterial colonisation of the damaged airways leads to chronic cough and sputum production, often with breathlessness and further
structural damage to the airways. Long-term macrolide antibiotic therapy may suppress bacterial infection and reduce inflammation,
leading to fewer exacerbations, fewer symptoms, improved lung function, and improved quality of life. Further evidence is required on
the efficacy of macrolides in terms of specific bacterial eradication and the extent of antibiotic resistance.
Objectives
To determine the impact of macrolide antibiotics in the treatment of adults and children with bronchiectasis.
Search methods
We identified trials from the Cochrane Airways Trials Register, which contains studies identified through multiple electronic searches
and handsearches of other sources. We also searched trial registries and reference lists of primary studies. We conducted all searches on
18 January 2018.
Selection criteria
We included randomised controlled trials (RCTs) of at least four weeks’ duration that compared macrolide antibiotics with placebo
or no intervention for the long-term management of stable bronchiectasis in adults or children with a diagnosis of bronchiectasis by
bronchography, plain film chest radiograph, or high-resolution computed tomography. We excluded studies in which participants had
received continuous or high-dose antibiotics immediately before enrolment or before a diagnosis of cystic fibrosis, sarcoidosis, or allergic
bronchopulmonary aspergillosis. Our primary outcomes were exacerbation, hospitalisation, and serious adverse events.
Data collection and analysis
Two review authors independently screened the titles and abstracts of 103 records. We independently screened the full text of 40 study
reports and included 15 trials from 30 reports. Two review authors independently extracted outcome data and assessed risk of bias for
each study.We analysed dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) or standardised mean
differences (SMDs). We used standard methodological procedures as expected by Cochrane.
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Main results
We included 14 parallel-group RCTs and one cross-over RCT with interventions lasting from 8 weeks to 24 months. Of 11 adult
studies with 690 participants, six used azithromycin, four roxithromycin, and one erythromycin. Four studies with 190 children used
either azithromycin, clarithromycin, erythromycin, or roxithromycin.
We included nine adult studies in our comparison betweenmacrolides and placebo and two in our comparison with no intervention. We
included one study with children in our comparison between macrolides and placebo and one in our comparison with no intervention.
In adults, macrolides reduced exacerbation frequency to a greater extent than placebo (OR 0.34, 95% confidence interval (CI) 0.22 to
0.54; 341 participants; three studies; I2 = 65%; moderate-quality evidence). This translates to a number needed to treat for an additional
beneficial outcome of 4 (95% CI 3 to 8). Data show no differences in exacerbation frequency between use of macrolides (OR 0.31,
95% CI 0.08 to 1.15; 43 participants; one study; moderate-quality evidence) and no intervention. Macrolides were also associated with
a significantly better quality of life compared with placebo (MD -8.90, 95% CI -13.13 to -4.67; 68 participants; one study; moderate-
quality evidence). We found no evidence of a reduction in hospitalisations (OR 0.56, 95% CI 0.19 to 1.62; 151 participants; two
studies; I2 = 0%; low-quality evidence), in the number of participants with serious adverse events, including pneumonia, respiratory
and non-respiratory infections, haemoptysis, and gastroenteritis (OR 0.49, 95% CI 0.20 to 1.23; 326 participants; three studies; I2
= 0%; low-quality evidence), or in the number experiencing adverse events (OR 0.83, 95% CI 0.51 to 1.35; 435 participants; five
studies; I2 = 28%) in adults with macrolides compared with placebo.
In children, exacerbation frequency was reduced more with macrolides than with placebo (IRR 0.50, 95% CI 0.35 to 0.71; 89 children;
one study; low-quality evidence). However there was no significant difference in this age group with regard to: hospitalisations (OR 0.28,
95% CI 0.07 to 1.11; 89 children; one study; low-quality evidence), serious adverse events, defined within the study as exacerbations of
bronchiectasis or investigations related to bronchiectasis (OR 0.43, 95% CI 0.17 to 1.05; 89 children; one study; low-quality evidence),
or adverse events (OR 0.78, 95% CI 0.33 to 1.83; 89 children; one study), in those receiving macrolides compared to placebo. The
same study reported an increase in macrolide-resistant bacteria (OR 7.13, 95% CI 2.13 to 23.79; 89 children; one study), an increase
in resistance to Streptococcus pneumoniae (OR 13.20, 95% CI 1.61 to 108.19; 89 children; one study), and an increase in resistance to
Staphylococcus aureus (OR 4.16, 95% CI 1.06 to 16.32; 89 children; one study) with macrolides compared with placebo. Quality of
life was not reported in the studies with children.
Authors’ conclusions
Long-term macrolide therapy may reduce the frequency of exacerbations and improve quality of life, although supporting evidence
is derived mainly from studies of azithromycin, rather than other macrolides, and predominantly among adults rather than children.
However, macrolides should be used with caution, as limited data indicate an associated increase in microbial resistance. Macrolides are
associated with increased risk of cardiovascular death and other serious adverse events in other populations, and available data cannot
exclude a similar risk among patients with bronchiectasis.
P L A I N L A N G U A G E S U M M A R Y
Macrolide antibiotics for bronchiectasis
Background to the question
Bronchiectasis is a long-term respiratory condition. The airways in the lungs are damaged, and people are prone to infection. Symptoms
are chronic cough and the production of sputum (coughed-up material (phlegm) from the lower airways). Moreover, bronchiectasis is
associated with a mortality rate more than twice that of the general population.
Long-term antibiotic therapy with macrolides (such as azithromycin, roxithromycin, erythromycin, and clarithromycin) may reduce
the cycle of reinfection, reduce symptoms, and improve quality of life. We wanted to do this review to look at the evidence on use
of macrolides in people with bronchiectasis. This review is intended to help people such as guideline producers, doctors, and patients
make decisions about whether to use or recommend macrolides.
Study characteristics
We found 15 studies that compared macrolides with placebo (a substance or treatment with no benefit) or no intervention. Eleven
studies involved 690 adults (aged 18 years and older) and four studies involved 190 children. Among adults, six used azithromycin,
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four roxithromycin, and one erythromycin. The four studies with children used azithromycin, clarithromycin, erythromycin, or
roxithromycin. This review is current to January 2018.
Main results
The studies on azithromycin reported improved quality of life in adults. We do not have sufficient evidence from other macrolides to
make a robust judgement on their use, and we similarly have insufficient evidence from children to draw clear conclusions.
Although we found only a few trials, they do show a possible increase in antibiotic resistance. Antibiotic resistance is seen when an
antibiotic becomes less effective at killing the bacteria causing the chest infection.
We know that macrolides are associated with higher risk of cardiovascular death and other serious adverse events when they are used to
treat other conditions. The data in our review suggest it is possible that people with bronchiectasis are at risk for these adverse effects
when taking macrolides.
Quality of the evidence
Generally the limited number of studies evaluating macrolides and the variation among them indicate that we cannot be sure of
the overall effect of their use in bronchiectasis. Further high-quality studies are needed to examine the role of long-term macrolide
antibiotics in the treatment of adults and children with bronchiectasis.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Macrolides compared with placebo for adults with bronchiectasis
Patient or population: adults with bronchiectasis
Setting: outpat ient clinics in Australia, Azerbaijan, Malaysia, Netherlands, New Zealand, and Thailand
Intervention: macrolides
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with macrolides
≥ 1 exacerbat ion
Follow-up: range 24
weeks to 52 weeks
714 per 1000 459 per 1000
(355 to 574)
OR 0.34
(0.22 to 0.54)
341
(3 RCTs)
⊕⊕⊕©
MODERATEa
2 studies azithromy-
cin (1750 mg/ week for
52 weeks; 1500 mg/
week for 6 months)
1 study erythromycin
(3500 mg/ week for 48
weeks)
Hospitalisat ion: all
cause
Follow-up: range 12
weeks to 52 weeks
133 per 1000 79 per 1000
(28 to 200)
OR 0.56
(0.19 to 1.62)
151
(2 RCTs)
⊕⊕©©
LOWb,c
2 studies azithromycin
(1000 mg/ week for 12
weeks; 1750 mg/ week
for 52 weeks)
Serious adverse events
Follow-up: range 24
weeks to 48 weeks
86 per 1000 44 per 1000
(18 to 104)
OR 0.49
(0.20 to 1.23)
326
(3 RCTs)
⊕⊕©©
LOWb,d
2 studies azithromy-
cin (1500 mg/ week for
6 months; 1000 mg/
week for 12 weeks)
1 study erythromycin
(3500 mg/ week for 48
weeks)
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All-cause mortality
Follow-up: range 8
weeks to 52 weeks
0 per 1000 0 per 1000
(0 to 0)
not est imable 540
(7 RCTs)
⊕⊕©©
Lowe,f
4 studies azithromycin
(1000 to 1750 mg/ week
for 12 to 52 weeks)
2 studies roxithromycin
(2100 mg/ week for 8 to
12 weeks)
1 study erythromycin
(3500 mg/ week for 48
weeks)
Quality of lif e: endpoint
assessed with SGRQ
Scale f rom 0 to 100
Follow-up: 12 weeks
Mean SGRQ score at
endpoint in placebo
groups was 39.1 points
MD 8.90 lower (13.13
lower to 4.67 lower)
- 68
(1 RCTs)
⊕⊕⊕©
Moderateb
1 study azithromycin
(1000 mg/ week for 12
weeks)
Quality of lif e: change
assessed with SGRQ
Scale f rom 0 to 100
Follow-up: range 8
weeks to 48 weeks
Mean change in SGRQ
score ranged f rom -1.3
to -8.9 points.
MD 2.86 lower
(5.67 lower to 0.04
lower)
- 305
(4 RCTs)
⊕⊕©©
LOWg,h
1 study azithromycin
(1500 mg/ week for 6
months)
1 study erythromycin
(3500 mg/ week for 48
weeks)
2 studies roxithromycin
(2100 mg/ week for 12
weeks; 2100 mg/ week
for 8 weeks)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT : randomised controlled trial; RR: risk rat io; SGRQ: St. George’s Respiratory Quest ionnaire.
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect5
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aEf fect observed only with azithromycin (one point deducted in relat ion to design and implementat ion of available studies
suggest ing likelihood of bias).
bUnclear allocat ion concealment and baseline imbalances on Lourdesamy (one point deducted in relat ion to design and
implementat ion of available studies suggest ing likelihood of bias).
cTwo small studies and wide conf idence interval (one point deducted for imprecision).
dWide conf idence interval (one point deducted for imprecision).
eIn three of the seven studies, study methods were not clearly reported (one point deducted in relat ion to design and
implementat ion of available studies suggest ing likelihood of bias).
f A total of 28 part icipants across four studies were lost to follow-up with no further details available and unclear details
of withdrawals in one study (one point deducted in relat ion to design and implementat ion of available studies suggest ing
likelihood of bias).
gRandomisat ion, blinding, and other study methods unclear in two studies (Asintam; Juthong) (one point deducted in relat ion
to design and implementat ion of available studies suggest ing likelihood of bias).
hWide conf idence interval and mean dif ference does not exceed the threshold for clinical signif icance (one point deducted
for imprecision).
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B A C K G R O U N D
Description of the condition
Bronchiectasis is a chronic respiratory disease characterised by ab-
normal and irreversible dilatation and distortion of the airways
(Pasteur 2010). Bacterial colonisation of the damaged airways
leads to chronic cough and sputum production, often with breath-
lessness and further structural damage to the airways. Diagnosis
is made by computed tomography (CT) scanning of the chest
when appropriate clinical symptoms are identified (Chang 2010),
but asymptomatic radiological evidence of bronchiectasis may be
noted (Kwak 2010).
Bronchiectasis has many causes, generally involving major or re-
peated insults to the lungs. Severe infections includingpneumonia,
tuberculosis, and pertussis may cause bronchiectasis, particularly
if they occur during childhood while the lungs are still developing.
Connective tissue disorders and defects in the immune system are
other common causes of bronchiectasis, but many cases are idio-
pathic. Cystic fibrosis leads to severe, progressive bronchiectasis
and usually is considered a separate entity from ’non-cystic fibrosis’
bronchiectasis. This review will exclude bronchiectasis secondary
to cystic fibrosis.
Prevalence estimates are unclear owing to variable diagnostic
strategies (Weycker 2005), a well as higher prevalence rates in
developing countries (Habesoglu 2011), but the global disease
burden is increasing, with mortality rising by 3% per year be-
tween 2001 and 2007, in England and in Wales (Roberts 2010),
and hospitalisations by 3% per year in the United States (Seitz
2010). Prevalence is higher in women and those over 60 years of
age (Roberts 2010; Seitz 2012). However, prevalence rates may
be increasing more rapidly than was previously estimated, with
67 cases per 100,000 general population reported in Germany
(Ringshausen 2015), and with UK prevalence rising from 350.5
to 566.1 in women and from 301.2 to 485.5 in men, affecting
around 262,900 adults (Quint 2016). Similarly, UK incidence
rates increased by 63% over nine years to 2013, rising from 21.2 to
35.2 in women and 8.2 to 26.9 in men, per 100,000 person-years
(Quint 2016). In paediatric populations, younger children and
more frequent exacerbations are associated with worse quality of
life (Kapur 2012). A higher prevalence of bronchiectasis has been
reported among indigenous children in Australia (15:1000) and
Alaska (16:1000) (Chang 2002). Incidence rates of 3.7 per 10,000
per year in children under 15 years of age have been reported in
New Zealand (Twiss 2005). This equates to a prevalence of 1:
3000 children overall and 1:625 children of Pacific Island descent
(Twiss 2005). However, these increases may be due to improved
diagnosis resulting from easier access to high-quality CT scanners,
rather than reflecting a true rise in prevalence (Goeminne 2016).
Estimated European mortality rates are 0.3 per 100,000 general
population in EU countries (ranging from 0.01 in Germany to
1.18 in theUK) and0.2per 100,000 innon-EUcountries (ranging
from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan), based on data to
2009 (European Lung White Book 2013). Recent age-adjusted
mortality rates in the UK are estimated to be 2.26 times higher in
women and 2.14 times higher in men compared with the wider
population (Quint 2016). This information is based on estimated
mortality rates for bronchiectasis of 1437.7 per 100,000 and for
the general population of 635.9 per 100,000 (Quint 2016).
Description of the intervention
Chronic airway infection with pathogens such as Pseudomonas
aeruginosa and Haemophilus influenzae and neutrophil-mediated
airway inflammation are key drivers of disease progression and
poor outcomes in bronchiectasis (Chalmers 2012;Chalmers 2014;
Finch 2015). Long-term antibiotic therapy therefore is often pre-
scribed with the intention of suppressing bacterial load and reduc-
ing airway inflammation (Chalmers 2012). This in turn aims to
reduce exacerbations, improve symptoms, and improve quality of
life (Haworth 2014). Prolonged antibiotic treatment can be ad-
ministered in the form of oral or inhaled antibiotics. Inhaled an-
tibiotics offer the advantage of delivering a higher dose of the drug
directly to the site of bronchiectasis infection, with less potential
for collateral damage and resistance; however, they are often time
consuming to administer (Brodt 2014). Oral antibiotics by con-
trast are typically cheaper and easier to administer than inhaled
antibiotics.
Oral antibiotics may be given at lower doses than those used to
treat acute infection, with the aims of reducing adverse effects and
promoting compliance (Haworth 2014).Macrolide antibiotics are
antibacterial agents with anti-inflammatory and immunomodu-
latory properties (Haworth 2014). Long-acting macrolide antibi-
otics such as azithromycin can be given intermittently rather than
requiring daily dosing. Penicillins, tetracyclines, and macrolides
have all been tested as prolonged therapy in bronchiectasis (Pasteur
2010). National guidelines for bronchiectasis, such as those pro-
vided by the British Thoracic Society, suggest that use of long-
term antibiotic treatment should be considered for patients with
three or more exacerbations per year (Pasteur 2010).
Long-term use of macrolides in bronchiectasis is supported by
their ease of administration, their effectiveness in cystic fibrosis and
other neutrophilic lung diseases, and their reported anti-inflam-
matory properties (Saiman 2003). Balanced against these traits is
the potential formacrolides to induce antibiotic resistance andpro-
duce antibiotic-related adverse effects, hearing impairment, and
cardiotoxicity (Serisier 2013a).
How the intervention might work
Exacerbations, symptoms, and quality of life are directly linked
to bacterial infection and airway inflammation in bronchiectasis
(Chalmers 2012; Chalmers 2014). Macrolides are given as both
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antibacterial and anti-inflammatory drugs, although it is unclear
which of these properties is primarily responsible for the clini-
cal effect observed in cystic fibrosis or bronchiectasis. Macrolides
bind reversibly to the 50s ribosomal subunit, preventing bacterial
protein synthesis (Haworth 2014). They therefore have broad ac-
tivity against Gram-positive organisms such as staphylococci and
streptococci and exhibit a degree of activity against Gram-negative
organisms such as Haemophilus bacteria. It is interesting to note
that macrolides show no bacteriocidal activity against P aeruginosa
but may modify virulence by interfering with quorum sensing and
virulence factors (Kohler 2010).
The anti-inflammatory effects of macrolides have been known
for decades and are classically demonstrated in their effectiveness
against diffuse panbronchiolitis (Amsden 2005). Macrolides con-
tain a macrocytic lactone ring that is thought to be responsible
for most anti-inflammatory effects (Haworth 2014). Macrolides
are classified according to the number of lactone rings as 14-, 15-
, and 16-member ring macrolides. Macrolides confer potentially
beneficial effects at every level of the ’vicious cycle’ of bronchiecta-
sis. They reduce the secretion of pro-inflammatory cytokines from
epithelial cells, inhibit leucocyte recruitment to the airway, inhibit
neutrophil activation, and reduce oxidative stress (Zarogoulidis
2012).
Thus potential benefits of macrolides include suppression of bac-
terial infection, leading to reduced exacerbations, reduced cough
and sputum production, and improved lung function and quality
of life.
Why it is important to do this review
Bronchiectasis is associated with a mortality rate more than twice
that of the general population - 2.26 times higher in women and
2.14 times higher in men (Quint 2016). Data on the economic
burden of bronchiectasis are few; however a 2001 US study re-
ported 2.0 more days in hospital, 6.1 more outpatient appoint-
ments, and 27.2 more days of antibiotic treatment (Weycker
2005). It is estimated that additional annual costs associated with
bronchiectasis ranged from USD 5681 to USD 7827 during the
period between 2001 and 2009 (Joish 2013; Seitz 2010; Weycker
2005).
Frequent exacerbations lead to impaired quality of life and pro-
gressive lung damage with permanent loss of lung function
(Martínez-García 2007). Therefore, drug interventions that are
effective in reducing the frequency of exacerbations should offer
both short-term and long-termbenefit for patientswith bronchiec-
tasis. A Cochrane Review of short-term antibiotics provided little
evidence on which to base a recommendation, with one small trial
showing evidence of global improvement and pathogen eradica-
tion in sputum (Wurzel 2011). Another Cochrane Review of long-
term antibiotic therapy included 18 trials of moderate quality and
provided evidence of reduced exacerbation frequency and hospi-
talisation but increased drug resistance (Hnin 2015). Neither of
these Cochrane Reviews examined effects by class of antibiotics,
and neither specifically created subgroups by macrolide therapy. A
Cochrane Overview concluded that further evidence is required
on the efficacy of antibiotics in terms of eradication of specific bac-
terial colonisation and the extent of antibiotic resistance (Welsh
2015). Recent recommendations from the European Task Force
on Bronchiectasis further reinforced the importance of this ques-
tion by identifying research on macrolide therapy as one of the key
priorities in bronchiectasis (Aliberti 2016). Macrolides may po-
tentially reduce exacerbations of bronchiectasis. Given their draw-
backs, particularly cardiac toxicity as described by Ray 2012 and
the potential for selecting antibiotic-resistant organisms as dis-
cussed by Leclercq 2002, robust evidence on the effectiveness of
macrolides is needed if they are to be used with confidence for this
indication.
This review is being conducted alongside two other, closely related
reviews: “Dual antibiotics for bronchiectasis” and“Head to head
trials of antibiotics for bronchiectasis”.
O B J E C T I V E S
To determine the impact of macrolide antibiotics in the treatment
of adults and children with bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of at least four
weeks’ duration. We included cross-over studies but used only data
from the first pre-cross-over phase to eliminate potentially irre-
versible carry-over effects (e.g. antibiotic resistance). We included
studies reported as full text, those published as abstract only, and
unpublished data.
Types of participants
We included adults and children with a diagnosis of bronchiectasis
by bronchography, plain film chest radiography, or high-resolution
computed tomography who reported daily sputum expectoration
for at least three months. We did not exclude participants whose
condition was diagnosed by radiography alone. When a study in-
cluded participants with different respiratory conditions, we in-
cluded the study only if investigators performed a separate sub-
group analysis for participants with bronchiectasis. We excluded
studies if participants had been receiving continuous or high-dose
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antibiotics immediately before enrolment, or if they had received
a diagnosis of cystic fibrosis, sarcoidosis, or allergic bronchopul-
monary aspergillosis. We defined children as individuals from six
months to 18 years of age.
Types of interventions
We included studies comparing macrolide antibiotics with
placebo, no intervention, or non-macrolide antibiotics for long-
term management of stable bronchiectasis and reporting these
different comparisons separately. We excluded studies looking at
short-termmacrolides formanagement (as opposed to prevention)
of exacerbations of bronchiectasis.
Types of outcome measures
Weused exacerbation andhospitalisation rates as reported by study
authors. We collected outcome data at a range of follow-up points
that best reflected available evidence from included studies (e.g.
end of study, end of follow-up, change from baseline).
Primary outcomes
1. Exacerbations (defined by study authors’ criteria)
2. Hospitalisation (defined by study authors’ criteria)
3. Serious adverse events defined by Hansen 2015, as follows:
adverse events that result in death or life-threatening events,
requirement for hospitalisation or prolongation of existing
hospitalisation, persistent or significant disability, or congenital
anomalies; or events that are considered medically important
Secondary outcomes
1. Sputum volume and purulence
2. Measures of lung function (e.g. forced expiratory volume in
one second (FEV1))
3. Systemic markers of infection (C-reactive protein (CRP))
4. Adverse events (e.g. cardiac arrhythmias, gastrointestinal
symptoms, hearing impairment)
5. Mortality (with this review indicating whether defined as
all-cause or bronchiectasis-related in individual studies)
6. Emergence of resistance to antibiotics
7. Exercise capacity (e.g. the Six-Minute Walk Distance test
(6MWD))
8. Health-related quality of life (e.g. St. George’s Respiratory
Questionnaire (SGRQ))
Reporting in the study one or more of the outcomes listed here
was not an inclusion criterion for this review.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from the following sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP 1967 to date.
5. Monthly searches of Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO 1937 to date.
6. Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in theCochraneAirwaysTrialsRegister are iden-
tified through search strategies based on the scope of Cochrane
Airways. We have provided details of these strategies, as well as a
list of handsearched conference proceedings, in Appendix 1. See
Appendix 2 for search terms used to identify studies for this review.
We also conducted a search of the US National Insti-
tutes of Health Ongoing Trials Register, ClinicalTrials.gov (
www.clinicaltrials.gov), and the World Health Organization In-
ternational Clinical Trials Registry Platform ( apps.who.int/
trialsearch).
We searched all databases from their inception to January 2018
and imposed no restrictions on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references and searched relevant manufac-
turers’ websites for study information. We searched PubMed (
www.ncbi.nlm.nih.gov/pubmed) for errata or retractions from in-
cluded studies published in full text and reported within the re-
view the date this was done.
Data collection and analysis
Selection of studies
Two review authors (DE and LF) independently screened titles
and abstracts for inclusion of all potential studies identified as a
result of the search and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We retrieved full-text
study reports/publications, and two review authors (CK and LF)
independently screened the full texts, identified studies for inclu-
sion, and identified and recorded reasons for exclusion of ineligible
studies. We encountered no disagreements, so the need to consult
a third review author (SS or SJM) did not arise. We identified and
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excluded duplicates and collated multiple reports of the same trial,
so that each trial rather than each report was the unit of interest
in the review. We recorded the selection process in detail in the
PRISMA flow diagram and the Characteristics of excluded studies
table (Moher 2009).
Data extraction and management
We used a data collection form that was piloted on at least one
study in the review to extract study characteristics and outcome
data. One review author (LF) extracted the following characteris-
tics from included studies.
1. Methods: study design, total duration, details of ’run-in’
period, number of centres and their locations, settings,
withdrawals, and dates the study was carried out.
2. Participants: number, mean age and range, gender,
bronchiectasis severity, diagnostic criteria, baseline lung
function, smoking history, inclusion and exclusion criteria.
3. Interventions and comparisons: intervention, comparison,
concomitant medications, and excluded medications.
4. Outcomes: primary and secondary outcomes reported and
follow-up time points.
5. Notes: funding source and notable conflicts of interest of
study authors.
Two review authors (LF and NR) independently extracted out-
come data from the included studies. When investigators did
not report outcome data in a usable way, we noted this in the
Characteristics of included studies table. We resolved disagree-
ments by reaching consensus or by involving a third review author
(SS or SJM). One review author (LF) transferred data into the Re-
view Manager 5 file (RevMan 2014), and a second review author
(SS) verified and validated the information. One review author
(CK) spot-checked study characteristics for accuracy against the
trial reports.
Assessment of risk of bias in included studies
Two review authors (NR and LF) independently assessed the risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
according to the domains below. We resolved disagreements by
discussion or by consultation with another review author (SS or
SJM).
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as bringing high, low, or
unclear risk, provided a quote from the study report, and recorded
our judgement in the ’Risk of bias’ table. We summarised risk of
bias judgements across different studies for each of the domains
listed and reported these in a ’Risk of bias summary table’ and a
’Risk of bias graph’. We considered blinding separately for differ-
ent key outcomes when necessary (e.g. for unblinded outcome as-
sessment, risk of bias for all-cause mortality may be very different
than for a patient-reported pain scale). When information on risk
of bias was related to unpublished data or correspondence with a
study author, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the previously published
protocol and have reported deviations from it in the Differences
between protocol and review section.
Measures of treatment effect
We analysed dichotomous data as odds ratios (ORs) and contin-
uous data as mean differences (MDs) or standardised mean dif-
ferences (SMDs). We analysed hospitalisation and exacerbation
rates as rate ratios when possible. We entered data as a scale with
a consistent direction of effect. We undertook meta-analyses only
when these were meaningful (i.e. when treatments, participants,
and the underlying clinical question were similar enough for pool-
ing to make sense). We narratively described skewed data reported
as medians and interquartile ranges, as well as data not suitable
for meta-analysis (e.g. data from mixed methods regression). Our
review did not include trials with multiple intervention arms, but
if future updates of the review should identify this type of trial,
we will include only the intervention arms relevant to this review.
When we combined two comparisons (e.g. drug A vs placebo and
drug B vs placebo) in the same meta-analysis, we halved the con-
trol group to avoid double-counting.
Unit of analysis issues
The study participant was the unit of analysis in all included stud-
ies. For exacerbation and admission rates, we focused on the num-
ber of events experienced by the participant during the trial. For
cross-over trials, we used only data from the first pre-cross-over
phase to minimise potential bias from carry-over effects.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. only abstract available). When this was not
possible and we thought that missing data might introduce seri-
ous bias, we explored the impact of including such studies in the
overall assessment of results by performing a sensitivity analysis.
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Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the stud-
ies in each analysis. When we identified substantial heterogeneity
(> 50%), we reported this in the text and explored possible causes
by conducting prespecified subgroup analyses (e.g. adults vs chil-
dren).
Assessment of reporting biases
We were not able to pool more than 10 studies for any compari-
son; therefore, we were unable to explore small-study effects and
publication biases by using a funnel plot.
Data synthesis
We included outcomes inmeta-analyses whenwe considered study
designs, interventions, and outcomes as sufficiently similar. When
we identified substantial heterogeneity (> 50%), we reported out-
comes in the text, revealing the direction and size of the effect,
along with the strength of the evidence (risk of bias). Antibiotic
studies varied by population, design, and outcomes. However, we
identified few studies for each comparison, and estimates from
a random-effects model therefore may have been unreliable, we
used a fixed-effect model, reported data with 95% confidence in-
tervals (CIs), and evaluated the impact of model choice by per-
forming a sensitivity analysis, when appropriate. We synthesised
and reported dichotomous and continuous data separately for each
outcome (e.g. exacerbation/no exacerbation or exacerbation dura-
tion), and when study authors reported both end-of-study point
estimates and change from baseline scores, we analysed these sep-
arately.
’Summary of findings’ tables
We created ’Summary of findings’ tables by using the following
primary and secondary outcomes: exacerbations, hospitalisations,
serious adverse events, deaths, and quality of life. We used the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness, and publication bias) to assess the qual-
ity of evidence from studies contributing data to meta-analyses
for these outcomes. We used methods and recommendations as
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), and we
used GRADEproGDT software (GRADEproGDT). We justified
all decisions to downgrade or upgrade the quality of evidence pro-
vided by studies by using footnotes and adding comments to aid
understanding when necessary.
Subgroup analysis and investigation of heterogeneity
Weplanned to carry out the following subgroup analyses, although
data were insufficient for comparisons of all subgroups. However,
we chose to present the data for different macrolides as subgroups
for all outcomes.
1. Macrolides versus other classes of long-term antibiotics.
2. Types of macrolides.
3. Dose and frequency.
4. Duration.
Weplanned touse the followingoutcomes in conducting subgroup
analyses.
1. Exacerbations.
2. Hospitalisations.
3. Serious adverse events.
We used the formal test for subgroup interactions provided in
Review Manager 5 (RevMan 2014).
Sensitivity analysis
We evaluated effects of methodological study quality by removing
studies at high or unclear risk of bias for the domains of random
sequence generation and allocation concealment.
R E S U L T S
Description of studies
Results of the search
A systematic search, conducted on 18 January 2018, identified
103 unique records of potentially relevant trials. Of these, we
considered 63 records irrelevant following inspection of their titles
and abstracts. We obtained and read full texts for the remaining
40 records and formally excluded eight records (documented in
Excluded studies). We contacted the authors of one study (two
records) awaiting classification (see Studies awaiting classification).
A total of 15 trials, with 30 records, met our inclusion criteria for
studies of macrolides for bronchiectasis. We have summarised the
selection process in the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
In 11 trials (Altenburg 2013; Asintam2012;Cymbala 2005;Diego
2013; Juthong 2011; Liu 2012; Liu 2014; Lourdesamy 2014;
Sadigov 2013; Serisier 2013;Wong 2012), study participants were
adults, and in the remaining four trials (Koh 1997; Masekela
2013; Valery 2013; Yalcin 2006), participants were children. See
Characteristics of included studies for further details. See Table 1
for an overview of study characteristics.
Methods
Fourteen of the 15 included studies were parallel-group RCTs,
and the remaining study was an RCT with a cross-over design
(Cymbala 2005). Nine trials were double-blind, five were open-
label, and one did not report information on study blinding. The
intervention duration ranged from eight weeks in Juthong 2011
to 24 months in Valery 2013. The percentage of participants who
withdrew after randomisation ranged from 0 in Juthong 2011and
Yalcin 2006 to 27% inMasekela 2013, with an average withdrawal
proportion of 8.7% across all included studies.
Seven trials were conducted in Asia (Asintam 2012; Juthong 2011;
Koh 1997; Liu 2012; Liu 2014; Lourdesamy 2014; Sadigov 2013);
three inAustralia/NewZealand (Serisier 2013; Valery 2013;Wong
2012); three in Europe (Altenburg 2013; Diego 2013; Yalcin
2006); one in South Africa (Masekela 2013); and one in the USA
(Cymbala 2005). Please see Figure 2 for the global distribution of
trials. The oldest study concluded in 1996 (Koh 1997), and the
most recent in 2013 (Lourdesamy 2014). Three studies recruited
participants through multiple centres (Altenburg 2013; Valery
2013;Wong 2012); the remainderwere conducted at single centres
(Figure 2).
Figure 2. Global distribution of studies.
Six trials used intention-to-treat analyses (Altenburg 2013;
Juthong 2011; Serisier 2013; Valery 2013; Wong 2012; Yalcin
2006), and seven trials included in analyses only participants who
completed the study (Cymbala 2005; Diego 2013; Koh 1997; Liu
2012; Liu 2014; Lourdesamy 2014; Masekela 2013); the analyses
performed in two studies were unclear (Asintam 2012; Sadigov
2013). Nine studies reported power calculations for sample size es-
timation (Altenburg 2013; Asintam 2012; Cymbala 2005; Diego
2013; Lourdesamy 2014; Masekela 2013; Serisier 2013; Valery
2013; Wong 2012), and all six remaining studies reported statisti-
cally significant results (Juthong 2011; Koh 1997; Liu 2012; Liu
2014; Sadigov 2013; Yalcin 2006).
Note:We could not include results fromCymbala 2005 in the review,
as data from the pre-cross-over phase alone were not available owing to
ineffective randomisation procedures. SeeCharacteristics of included
studies and the associated risk of bias table for additional details.
Participants
We chose to present separately data from adults and children and
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data on different macrolides.
Adults
Eleven studies included a total of 690 adults aged 18 years and
older, with a diagnosis of bronchiectasis confirmed by high-res-
olution computed tomography (HRCT). Three studies specified
the following numbers of exacerbations in the preceding year as
screening criteria: at least three (Altenburg 2013); two (Serisier
2013); and one (Wong 2012). The number of randomised partic-
ipants in each study ranged from 12 in Cymbala 2005 to 141 in
Wong 2012, with amean age range of 48 years in Liu 2012 to 70.8
years in Cymbala 2005, although one study did not report this
information (Sadigov 2013). Data on gender were missing for 81
randomised participants: Three trials reported gender distribution
only for those who completed the study (Cymbala 2005; Diego
2013; Liu 2014), and one did not report gender (Sadigov 2013).
Of 601 participants for whom data were available, 373 were fe-
male and 236 were male, with the percentage of male participants
ranging from 23% in Asintam 2012 to 54% in Juthong 2011,
across individual studies.
Three studies reported baseline disease severity in terms of Bhalla
score: 9.5 (Liu 2014), 12.5 (Asintam 2012), and 26.5 (Diego
2013). Seven studies reported baseline FEV1 % predicted ranging
from moderate impairment at 57% of predicted (Diego 2013), to
mild impairment at 80.7%of predicted (Altenburg 2013), and two
further studies reported baseline FEV1 as 1.08 L in Lourdesamy
2014 and 1.42 L in Juthong 2011. The remaining two studies did
not report baseline lung function (Liu 2012; Sadigov 2013). Seven
studies reported smoking status, with the proportion of current
smokers ranging from none in Asintam 2012 and Serisier 2013
to 28% in Lourdesamy 2014 one study reported 66% current or
ex-smokers (Cymbala 2005), and four studies did not report this
information (Diego 2013; Liu 2012; Sadigov 2013; Wong 2012).
Children
Four studies included a total of 190 randomised children, consist-
ing of 81 girls and 98 boys (gender of participants lost to follow-
up was not reported in Masekela 2013), younger than 18 years
of age (Koh 1997; Masekela 2013; Valery 2013; Yalcin 2006).
Four studies reported a diagnosis of bronchiectasis by HRCT, and
Valery 2013 included children with chronic suppurative lung dis-
ease, thus meeting clinical criteria when HRCT was not available.
Sample sizes ranged from 25 in Koh 1997 to 89 children in Valery
2013, with mean age ranging from four years in Valery 2013 to 13
years in Koh 1997. Participants in Valery 2013 were indigenous
children from Australia and New Zealand. Children in Masekela
2013 had confirmed HIV infection, were receiving highly active
antiretroviral therapy (HAART), and had undergone a sweat test
to rule out cystic fibrosis. Children in Koh 1997 had increased
airway responsiveness, confirmed by a metacholine challenge test.
Valery 2013 specified at least one exacerbation in the preceding
year as one of its inclusion criteria.
Three studies reported baseline FEV1 % predicted as follows:
54.8% (Masekela 2013), 76.5% (Yalcin 2006), and 83% (Koh
1997). Valery 2013 did not report lung function.
Interventions
Adults
The 11 adult studies evaluated three types of oral macrolides. Six
studies used azithromycin with doses ranging from 750 to 1750
mg per week for a period of 12 to 52 weeks, four studies used
roxithromycin with doses ranging from 1050 to 2100 mg per
week for 8 to 24 weeks, and one study used erythromycin at a
dose of 3500 mg per week for 48 weeks. Seven studies compared
the intervention with placebo (Altenburg 2013; Asintam 2012;
Juthong 2011; Lourdesamy 2014; Sadigov 2013; Serisier 2013;
Wong 2012), three studies compared the intervention with no
intervention (Cymbala 2005; Diego 2013; Liu 2014), and one
study compared the intervention plus an antimucolytic with the
antimucolytic alone (Liu 2012). We have summarised in Table 1
further details of interventions provided in individual studies.
Note: For all outcomes from Diego 2013, we have included only
the mean change score, pending clarification by study authors of
reported standard deviations. Therefore, we have included these
data in the text narratively.
Outcomes
One study reported all of our prespecified outcomes (Altenburg
2013).
Seven adult studies reported the frequency of exacerbations
(Altenburg 2013; Asintam 2012; Diego 2013; Liu 2014; Sadigov
2013; Serisier 2013; Wong 2012), and three reported the time to
first exacerbation (Altenburg 2013; Sadigov 2013; Wong 2012).
Two children’s studies reported the frequency of exacerbations
(Masekela 2013; Valery 2013), and one also reported the time
to first exacerbation and the duration of the exacerbation (Valery
2013).
Two adult studies reported hospitalisations (Altenburg 2013;
Lourdesamy 2014), as did one paediatric study (Valery 2013).
All three adult studies reported serious adverse events (Lourdesamy
2014; Serisier 2013; Wong 2012), as did one study in which the
participants were children (Valery 2013).
Five of the adult studies reported sputum volume (Asintam 2012;
Cymbala 2005; Diego 2013; Lourdesamy 2014; Serisier 2013), as
did two paediatric studies (Koh 1997; Yalcin 2006). Data from
Cymbala 2005 were not usable (see note above).
Nine adult studies reported lung function, measured as FEV1 or
forced vital capacity (FVC), or both (Altenburg 2013; Asintam
2012; Cymbala 2005; Diego 2013; Juthong 2011; Lourdesamy
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2014; Sadigov 2013; Serisier 2013; Wong 2012), as did all four
paediatric studies (Koh 1997; Masekela 2013; Valery 2013; Yalcin
2006). Data fromCymbala 2005 were not usable (see note above).
Two adult studies reported FEV1 before and after bronchodilation
(Diego 2013;Wong 2012), and one also reported FVC before and
after bronchodilation (Wong 2012). The remaining studies did
not specify whether lung function was measured before or after
bronchodilation.
Three adult studies reported systemic markers such as C-reactive
protein (Altenburg 2013; Masekela 2013; Serisier 2013).
Five adult studies reported adverse events (Altenburg 2013;
Juthong 2011; Lourdesamy 2014; Serisier 2013; Wong 2012), as
did two studies with children (Liu 2014; Valery 2013).
All 15 studies directly reported or inferred all-cause mortality due
to completion of the study period by all participants (Altenburg
2013; Asintam 2012; Cymbala 2005; Diego 2013; Juthong 2011;
Koh 1997; Liu 2012; Liu 2014; Lourdesamy 2014; Masekela
2013; Sadigov 2013; Serisier 2013; Valery 2013; Wong 2012;
Yalcin 2006).
Four adult studies reported the emergence of resistance to antibi-
otics (Altenburg 2013; Juthong 2011; Serisier 2013;Wong 2012),
as did one study that included children (Valery 2013).
Two adult studies reported exercise capacity as measured by the
6MWD test (Serisier 2013; Wong 2012).
Nine adult studies reported health-related quality of life using
SGRQ (Altenburg 2013; Asintam 2012; Diego 2013; Juthong
2011; Liu 2012; Liu 2014; Lourdesamy 2014; Serisier 2013;Wong
2012).
Note: Eight studies reported a formal sample size calculation
(Altenburg 2013; Asintam 2012; Cymbala 2005; Diego 2013;
Lourdesamy 2014; Serisier 2013; Valery 2013; Wong 2012), but
two of these studies did not recruit the target number of par-
ticipants (Asintam 2012; Cymbala 2005). Six studies provided
details of online trial registration (Altenburg 2013; Diego 2013;
Lourdesamy 2014; Serisier 2013; Valery 2013;Wong 2012). Eight
studies included conflict of interest statements (Altenburg 2013;
Cymbala 2005; Juthong 2011; Liu 2014; Lourdesamy 2014;
Serisier 2013; Valery 2013; Wong 2012). Nine studies explicitly
stated funding sources for the study (Altenburg 2013; Cymbala
2005; Diego 2013; Juthong 2011; Liu 2014; Lourdesamy 2014;
Serisier 2013; Valery 2013; Wong 2012), but only six studies re-
ported the role of funding sources in the trial (Altenburg 2013;
Cymbala 2005; Lourdesamy 2014; Serisier 2013; Valery 2013;
Wong 2012).
Subgroup analysis
One study with children conducted several post hoc subgroup
analyses based on intervention compliance, intervention duration,
bronchiectasis diagnosis, frequency of exacerbations at baseline,
and positive bacterial infection at the beginning of the trial (Valery
2013).
Excluded studies
We excluded eight studies from this review. Six of these were not
RCTs (Kudo 1988; Min 1988; Ming 2005; Rikitomi 1988; Saito
1988; Unoura 1986), one study was of less than four weeks’ du-
ration and therefore did not meet our inclusion criteria (Tagaya
2002), and one study served as the protocol for a trial (Chang
2013). Please see Characteristics of excluded studies for additional
details.
Risk of bias in included studies
Full details of the risk of bias judgements can be found in the
’Risk of bias’ section at the end of each Characteristics of included
studies table. Figure 3 and Figure 4 also provide a summary of
the risk of bias in all included studies. Two independent review
authors (LF and NR) independently assessed the risk of bias for
each of the included studies and reached agreement.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Review authors considered themethods used to generate randomi-
sation sequences as low risk in six studies (Altenburg 2013; Liu
2012; Lourdesamy 2014; Serisier 2013;Valery 2013;Wong 2012).
Lourdesamy 2014 and Valery 2013 randomised participants using
computer-generated random numbers in a 1:1 ratio, and Valery
2013 also reported using a block design. Altenburg 2013 described
an independently performed computer-generated random alloca-
tion sequence that used a permuted block size of 10. Serisier 2013
also used a computer-generated random allocation sequence but
with block sizes of 2, 4, and 8, and stratified patients by baseline
sputum Pseudomonas. Wong 2012 used a similar sequence gener-
ation with block size of 6 and stratified participants by centre. Liu
2012 randomised participants by using random number tables.
The remainingnine studies providedunclear details regarding gen-
eration of the randomisation sequence (Asintam 2012; Cymbala
2005; Diego 2013; Juthong 2011; Koh 1997; Liu 2014; Masekela
2013; Sadigov 2013; Yalcin 2006).
We judged allocation concealment as having low risk of bias in four
studies (Altenburg 2013; Serisier 2013; Valery 2013;Wong 2012),
andwe assignedunclear risk in 11 studies (Asintam 2012;Cymbala
2005; Diego 2013; Juthong 2011; Koh 1997; Liu 2012; Liu 2014;
Lourdesamy 2014; Masekela 2013; Sadigov 2013; Yalcin 2006).
Altenburg 2013 assigned identification codes with double-blind
allocation to treatment groups. Valery 2013 used sequentially
numbered, double-sealed, opaque envelopes to conceal group al-
location. Serisier 2013 used an independent trial pharmacist to
dispense blinded study drug according to the randomisation se-
quence. Wong 2012 randomly assigned participants to groups us-
ing a study-independent statistician. Studies considered at unclear
risk of allocation concealment bias did not provide adequate de-
tails of study methods to inform a clear judgement.
Blinding
We judged performance of the trial to be at low risk of bias in
six studies (Altenburg 2013; Juthong 2011; Lourdesamy 2014;
Serisier 2013; Valery 2013; Wong 2012). Juthong 2011 and
Altenburg 2013 reported identical tablets in both groups. Juthong
2011 Lourdesamy 2014, Serisier 2013 Valery 2013, and Wong
2012 stated that study personnel (patients, supervisors, staff, re-
searchers, investigators) were blinded to treatment allocation at all
times. We judged three studies as having high risk of performance
bias, as they were open-label trials (Diego 2013; Liu 2012; Liu
2014). Investigators reported methods in the remaining studies
in insufficient detail to permit a clear judgement of performance
bias (Asintam 2012; Cymbala 2005; Koh 1997; Masekela 2013;
Sadigov 2013; Yalcin 2006).
Six studies clearly stated blinding of outcome assessments (de-
tection bias); we therefore judged these studies to be low risk of
bias (Altenburg 2013; Liu 2012; Lourdesamy 2014; Serisier 2013;
Valery 2013; Wong 2012). However, the remaining nine studies
did not report methods in sufficient detail to inform a clear judge-
ment of the risk of detection bias (Asintam 2012; Cymbala 2005;
Diego 2013; Juthong 2011; Koh 1997; Liu 2014;Masekela 2013;
Sadigov 2013; Yalcin 2006).
Incomplete outcome data
We judged incomplete outcome data (attrition bias) to introduce
low risk of bias in nine studies (Altenburg 2013; Juthong 2011;
Koh 1997; Liu 2014; Lourdesamy 2014; Serisier 2013; Valery
2013; Wong 2012; Yalcin 2006). Four studies reported no drop-
outs (Altenburg 2013; Juthong 2011; Serisier 2013; Yalcin 2006).
Five studies clearly reported attrition rates and reasons for with-
drawal (Koh 1997; Liu 2014; Lourdesamy 2014; Valery 2013;
Wong 2012). We judged the remaining six studies to have un-
clear risk of attrition bias owing to insufficient reporting (Asintam
2012; Cymbala 2005; Diego 2013; Liu 2012; Masekela 2013;
Sadigov 2013).
Selective reporting
We judged six of the included studies to have low risk of re-
porting bias (selective reporting) (Altenburg 2013; Diego 2013;
Lourdesamy 2014; Serisier 2013; Valery 2013; Wong 2012), as
the study protocols were available, and all outcomes of interest
had been reported in the prespecified way. We judged the risk of
reporting bias as unclear in nine studies (Asintam 2012; Cymbala
2005; Juthong 2011; Koh 1997; Liu 2012; Liu 2014; Masekela
2013; Sadigov 2013; Yalcin 2006), as a full trial protocol was not
available.
Other potential sources of bias
We did not identify any other potential sources of bias in five
studies (Altenburg 2013; Diego 2013; Serisier 2013; Valery 2013;
Wong 2012), but we could not adequately assess this in seven
other included studies (Asintam 2012; Juthong 2011; Koh 1997;
Liu 2012; Liu 2014; Masekela 2013; Sadigov 2013). We judged
three studies to have high risk of other potential sources of bias
(Cymbala 2005 Lourdesamy 2014; Yalcin 2006).Group allocation
was ineffective in the pre-cross-over phase of Cymbala 2005, with
eight of 11 participants receiving the intervention. In Lourdesamy
2014, baseline sputum volume (primary outcome) was signifi-
cantly higher in the intervention arm compared with the placebo
group. Similarly, in Yalcin 2006, baseline cytokine assay levels were
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again significantly higher in the intervention group comparedwith
the placebo group.
Effects of interventions
See: Summary of findings for the main comparisonMacrolides
compared with placebo for adults with bronchiectasis; Summary
of findings 2 Macrolides compared with no intervention for
adults with bronchiectasis; Summary of findings 3 Macrolides
compared with placebo for children with bronchiectasis;
Summary of findings 4 Macrolides compared with no
intervention for children with bronchiectasis
Macrolide versus placebo: adults
Primary outcomes
Exacerbations
Two adult studies of azithromycin - Altenburg 2013 and Wong
2012 - and one adult study of erythromycin - Serisier 2013 - with a
total of 341 participants were included in a meta-analysis. Results
show that macrolides reduced the frequency of exacerbations to a
greater extent than placebo (OR 0.34, 95% CI 0.22 to 0.54; I2
= 65%; Analysis 1.1; moderate-quality evidence). This translates
to 714 per 1000 in the placebo group experiencing one or more
exacerbation compared with 459 per 1000 in the macrolide group
(95%CI 355 to 574) or a number needed to treat for an additional
beneficial outcome (NNTB) of 4 (95% CI 3 to 8) (Figure 5).
Figure 5. Analysis 1.1. Cates plot showing the absolute reduction in numbers of participants experiencing
one or more exacerbations in adults treated with macrolides compared with placebo (OR 0.34, 95% CI 0.22 to
0.54). 714 people per 1000 in the placebo group experienced one or more exacerbations compared with 459
(95% CI 355 to 574) per 1000 in the macrolide group.
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As heterogeneity was substantial, we tested the impact of a ran-
dom-effects model on the pooled effect size, which remained un-
changed (OR 0.34, 95% CI 0.15 to 0.75). However, we noted
significant differences between azithromycin and erythromycin
subgroups (test for subgroup differences: Chi2 = 5.63, df = 1 (P
= 0.02), I2 = 82.2%) and beneficial effects related to the two
azithromycin studies (OR 0.23, 95% CI 0.13 to 0.40; I2 = 0%)
(Altenburg 2013;Wong 2012). Data show no differences between
groups in the erythromycin study (OR 0.74, 95% CI 0.34 to
1.63). Two further studies did not report exacerbations in suffi-
cient detail for inclusion in meta-analyses. In one study of azithro-
mycin (1500 mg/week for six months) involving 65 adults, trial
authors reported that the intervention “significantly decreased the
rate of event-based exacerbations and significantly increased the
time to the first event-based exacerbation compared to placebo”,
but no further details were available (Sadigov 2013). In another
study of roxithromycin involving 30 adults, two participants in
the intervention group and one participant in the control group
developed an exacerbation but researchers reported no further de-
tails (Asintam 2012).
Three adult studies reported significantly reduced incidence rate
ratios in the intervention group as follows: 0.48 fewer exacerba-
tions per year (95%CI 0.65 to 0.26) (Altenburg 2013); 0.57 fewer
exacerbations per year (95% CI 0.77 to 0.42) (Serisier 2013); and
0.38 fewer exacerbations per year (95% CI 0.54 to 0.25) (Wong
2012).
One adult study reported time to first exacerbation following a
post hoc analysis, with a hazard ratio of 0.29 (95% CI 0.16 to
0.51) favouring azithromycin (Altenburg 2013).
Hospitalisations
We included in ameta-analysis two studies of azithromycin involv-
ing 151 adults (Altenburg 2013; Lourdesamy 2014); results show
no evidence of a reduction in hospitalisations in the azithromycin
group compared with the placebo group (OR 0.56, 95% CI 0.19
to 1.62; I2 = 0%; Analysis 1.2; low-quality evidence), although
these results should be interpreted with caution owing to the low
event rate.
Serious adverse events
Meta-analysis included two studies of azithromycin involving 209
adults (Lourdesamy 2014; Wong 2012), along with one study
of erythromycin with 117 adults (Serisier 2013). Serious adverse
events included pneumonia, respiratory and non-respiratory in-
fections, haemoptysis, gastroenteritis, hernia, congestive heart fail-
ure, stroke, and skin carcinoma. Results show no difference in
the numbers of participants with serious adverse events between
study groups (OR 0.49, 95% CI 0.20 to 1.23; I2 = 0%; Analysis
1.3; low-quality evidence) and no evidence of subgroup differ-
ences between azithromycin and erythromycin (test for subgroup
differences: Chi2 = 0.48, df = 2 (P = 0.79), I2 = 0%), although re-
sults should be interpreted with caution owing to low event rates.
Removing the study with unclear risk of bias for allocation con-
cealment - Lourdesamy 2014 - from the meta-analysis had little
impact on the pooled treatment effect (OR 0.39, 95% CI 0.12 to
1.23; I2 = 0%).
Secondary outcomes
Sputum volume and purulence
One study of azithromycin (1000 mg/week for 12 weeks) with
78 adults reported no difference in sputum volume between
study groups (MD 3.70, 95% CI -5.78 to 13.18; Analysis 1.4)
(Lourdesamy 2014). One study of erythromycin (3500 mg/week
for 48 weeks) with 117 adults reported a significant reduction in
the change from baseline in 24-hour sputumweight, favouring the
intervention (median change -4.4 grams, interquartile ratio (IQR)
-7.8 to -1; P = 0.01) (Serisier 2013). One study of roxithromycin
(2100 mg/week for 12 weeks) with 30 adults reported no improve-
ment in sputum volume in either study group but provided no
further details (Asintam 2012).
Measures of lung function
Forced expiratory volume in one second (FEV1)
Seven adult studies reported FEV1 as litres, percent of predicted, or
both (Altenburg 2013; Asintam 2012; Juthong 2011; Lourdesamy
2014; Sadigov 2013; Serisier 2013; Wong 2012). One trial of
azithromycin (1000 mg/week for 12 weeks) with 78 participants
showed no evidence of benefit in FEV1 %predicted from the inter-
vention at the end of the study (MD2.98, 95%CI -6.15 to 12.11;
Analysis 1.5) (Lourdesamy 2014).One trial of azithromycin (1750
mg/week for 52 weeks) with 83 participants reported an increase
of 1.03% in FEV1 % predicted in the intervention group every
three months compared with a decrease of 0.10% in the placebo
group (P = 0.047) (Altenburg 2013). One trial of erythromycin
(3500 mg/week for 48 weeks) with 117 participants reported a
significant difference in FEV1 %predicted change from baseline
between groups, favouring macrolides (MD 2.40, 95% CI 0.34
to 4.46; Analysis 1.6) (Serisier 2013). One study of azithromycin
(1500mg/week for 6months)with 65 participants reported signif-
icant improvements in prebronchodilator and postbronchodilator
FEV1 but provided no further details (Sadigov 2013). One study
of roxithromycin (2100 mg/week for 12 weeks) with 30 partic-
ipants reported no improvement in either study group but pro-
vided no further details (Asintam 2012).
A meta-analysis of data from two studies showed no benefit from
azithromycin or roxithromycin in FEV1 at the end of the study
(MD 0.02 L, 95% CI -0.17 to 0.22; Analysis 1.7) (Juthong 2011;
Lourdesamy 2014). Results show were no significant differences
between the two macrolides (test for subgroup differences: Chi2 =
0.43, df = 1 (P = 0.51), I2 = 0%). Another study of azithromycin
(1500 mg/week for 6 months) with 141 participants also showed
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no benefit from the intervention in change in FEV1 during the
study (MD 0.04 L, 95% CI -0.03 to 0.11; Analysis 1.8) (Wong
2012).
Forced vital capacity (FVC)
Four adult studies reported FVC as percent of predicted, in litres,
or both ways (Altenburg 2013; Juthong 2011; Lourdesamy 2014;
Wong 2012). One trial of azithromycin (1000 mg/week for 12
weeks) with 78 participants showed no benefit from the interven-
tion at the end of the study in terms of FVC % predicted (MD
1.07, 95% CI -9.27 to 11.41; Analysis 1.9) (Lourdesamy 2014).
Another study of azithromycin (1750 mg/week for 52 weeks) with
83 participants reported an increase in FVC of 1.33% predicted
in the intervention group and a decrease of 0.30% predicted in
the placebo group every three months (Altenburg 2013).
A meta-analysis of data from two studies with 94 participants
showed no benefit at the end of the study from azithromycin
or roxithromycin in terms of FVC (MD 0.08 L, 95% CI -0.19
to 0.36; Analysis 1.10) (Juthong 2011; Lourdesamy 2014). Re-
sults show no significant differences between the two macrolides
(test for subgroup differences: Chi2 = 1.57, df = 1 (P = 0.21), I
2 = 36.3%). One study of azithromycin (1500 mg/week for six
months) with 141 participants showed no benefit from the inter-
vention in changes in FVC (MD 0.08 L, 95% CI -0.53 to 0.69;
Analysis 1.11) (Wong 2012).
FEV1/FVC ratio
One study of azithromycin (1000 mg/week for 12 weeks) with 78
participants reported the FEV1/FVC ratio showing no evidence of
benefit from the intervention at the end of the study (MD 3.57,
95% CI -3.89 to 11.03; Analysis 1.12) (Lourdesamy 2014).
Systemic markers of infection
One trial of azithromycin (1750 mg/week for 52 weeks) with 83
participants reported no significant differences between median
CRP values at the end of the study (azithromycin 2.6 mg/dL,
IQR 1.5 - 7; control 3.9 mg/dL, IQR 2 - 6.15) and no changes
in serum levels, although P values were not reported (Altenburg
2013). Similarly, one trial of erythromycin (3500 mg/week for
48 weeks) with 117 participants reported no differences between
groups in CRP levels (median change difference -0.2 mg/L, IQR
-1.5 to 1.2), although again significance values were not reported
(Serisier 2013).
Adverse events
Five studies of three different macrolides (azithromycin, ery-
thromycin, and roxithromycin) with 435 adult participants were
included in a meta-analysis (Altenburg 2013; Juthong 2011;
Lourdesamy 2014; Serisier 2013; Wong 2012), showing no dif-
ferences between study groups in the numbers of people experi-
encing adverse events (OR 0.83, 95% CI 0.51 to 1.35; I2 = 28%;
Analysis 1.13). Trials provided no evidence of differences between
the three different macrolides (test for subgroup differences: Chi2
= 2.07, df = 2 (P = 0.36), I2 = 3.3%). Removing two studies from
the analysis with unclear risk of bias for sequence generation or
allocation concealment had little impact on the pooled treatment
effect (OR 0.83, 95% CI 0.50 to 1.39; I2 = 27%) (Juthong 2011;
Lourdesamy 2014).
All-cause mortality
Data show no deaths during the intervention period in six of
the adult studies (Altenburg 2013; Asintam 2012; Juthong 2011;
Sadigov 2013; Serisier 2013; Wong 2012). One study of azithro-
mycin (1000 mg/week for 12 weeks) with 78 participants reported
no deaths in the placebo group and two deaths in the intervention
group attributed to bronchopneumonia and not considered treat-
ment-related (Lourdesamy 2014). In performing our GRADE as-
sessment, we judged this outcome to be of low quality (Summary
of findings for the main comparison).
Emergence of resistance to antibiotics
One study of azithromycin with 83 adults reported no differences
between groups in the emergence of resistance to antibiotics (OR
0.71, 95% CI 0.30 to 1.69; Analysis 1.14) (Altenburg 2013). In
another study of roxithromycin (2100 mg/week for 8 weeks) with
26 adults, none of the participants experienced antibiotic resis-
tance to any bacterial strain (Juthong 2011). However, a study of
erythromycin (3500 mg/week for 48 weeks) with 117 participants
reported a higher proportion of macrolide-resistant oropharyngeal
streptococci in the intervention group compared with the placebo
group (median change difference 25.5%, IQR 15% to 33.7%; P
= 0.001) (Serisier 2013).
Exercise capacity
One study of erythromycin (3500mg/week for 48weeks)with 117
adults reported no differences in the change in 6MWD between
study groups (MD -6.30, 95% CI -28.86 to 16.26; Analysis 1.15)
(Serisier 2013). Similarly, a study of azithromycin (1500 mg/week
for 6 months) with 141 adults reported no significance difference
in change in 6MWD between study groups (mean change differ-
ence 6.48 m, 95% CI -11.28 to 24.22; P = 0.4) (Wong 2012).
Health-related quality of life
One study with 68 adults showed a significantly lower (better)
SGRQ total score at the end of the study in the intervention group
compared with the placebo group (MD -8.90, 95% CI -13.13 to
-4.67; Analysis 1.16; moderate-quality evidence) and an MD that
exceeded the 4-unit threshold of clinical significance (Lourdesamy
2014). We included in a meta-analysis four adult studies with 305
participants showing greater improvements from baseline to study
endpoint in quality of life with macrolides (MD -2.86, 95% CI -
5.67 to -0.04; Analysis 1.17; low-quality evidence) (Asintam 2012;
Juthong 2011; Serisier 2013;Wong 2012). Although data showno
significant differences between azithromycin and roxithromycin
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(test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =
0%), the beneficial effect was largely observed in the azithromycin
group. Differences between groups in all four studies were below
the threshold of clinical significance. Removing from the meta-
analysis the two studies with unclear risk of bias for sequence gen-
eration and allocation concealment had no impact on the pooled
treatment effect (MD -2.97, 95% CI -5.94 to -0.00; I2 = 0%)
(Asintam 2012; Juthong 2011).
One study of azithromycin (1750 mg/week for 52 weeks) with 83
participants reported a significant improvement in quality of life
(SGRQ total) with the intervention compared with placebo (in-
tervention group mean change -6.09, control group mean change
-2.06; P = 0.05) (Altenburg 2013).
Macrolide versus no intervention: adults
Primary outcomes
Exacerbations
One study of roxithromycin with 43 adults (1050 mg/week 6
months) did not find a clear difference in the frequency of ex-
acerbations between groups (OR 0.31, 95% CI 0.08 to 1.15;
Analysis 2.1; moderate-quality evidence; Summary of findings 2)
(Liu 2014).
None of the included studies reported our other primary out-
comes: hospitalisation and adverse or serious adverse events.
Secondary outcomes
Sputum volume and purulence
One study of azithromycin with 30 adults (750 mg/week 3
months) reported a decrease in sputum volume with macrolides
(MD -11.00 mL/d; P < 0.05) (Diego 2013). Following the inter-
vention, sputum volume decreased by 8.9 mL/d in the azithro-
mycin group and increased by 2.1 mL/d in the control group by
three months. Data show no differences in changes in sputum pu-
rulence scores between groups (mean change score: azithromycin
0.8, control 0.7) by three months.
Measures of lung function
One study of azithromycin with 30 adults (750 mg/week 3
months) found no differences between groups in FEV1 or FVC
(Diego 2013). Relative to baseline, FEV1 increased by 0.06 L
and 0.04 L in azithromycin and control groups, respectively, and
FVC decreased by 0.07 L and 0.08 L in azithromycin and control
groups, respectively, by three months.
Systemic markers of infection
One study of azithromycin with 30 adults (750 mg/week 3
months) found no differences between groups in CRP levels
(Diego 2013). This study reported a reduction in CRP levels by
three months compared with baseline in both groups: mean re-
duction: -17 in the azithromycin group, -11 in the control group.
Adverse events
One adult study reported adverse events as event rates but did not
report the number of participants experiencing at least one adverse
event (Liu 2014).
Mortality
Two adult studies reported no deaths during the study (Diego
2013; Liu 2014). Through GRADE assessment, we judged this
outcome to be of very low quality (Summary of findings 2).
Quality of life
Two roxithromycin studies with 89 adults (1050 mg/week
6 months) reported significantly better quality of life with
macrolides comparedwith no intervention at the endof sixmonths
(MD -8.81, 95%CI -14.33 to -3.28; Analysis 2.2;moderate-qual-
ity evidence) (Liu 2012; Liu 2014). One study of azithromycin
with 30 adults (750 mg/week for 3 months) reported a significant
improvement in quality of life, measured by the SGRQ total score,
after three months compared with no intervention (MD -12.00;
P < 0.05; low-quality evidence) (Diego 2013). The total score de-
creased by 7.9 units in the azithromycin group and increased by
4.1 units in the control group. It was not considered appropriate
to combine these outcomes in a meta-analysis owing to differences
in macrolides, doses, and study duration.
The included studies did not report our other secondary outcomes
- exercise capacity and resistance to antibiotics.
Macrolide versus placebo: children
Primary outcomes
Exacerbations
Two studies reported exacerbation frequency in children. One
study of azithromycin (30 kg/week for up to 24 months) reported
that in children, exacerbation frequency was reduced more with
macrolides than with placebo (IRR 0.50, 95% CI 0.35 to 0.71;
89 children; one study; low-quality evidence). However, we feel
this should be interpreted with a degree of caution as the same
study reported no significant benefit from the intervention in the
number of children with at least one exacerbation (OR 0.40, 95%
CI 0.11 to 1.41; low-quality evidence) nor in the time to first
exacerbation (hazard ratio 0·63, 95% CI 0·40-1·00; log-rank P =
0.12) (Valery 2013). Another study of erythromycin (875 < 15
kg > 1750 mg/week for 52 weeks) in 42 children reported that
three children in the intervention group remained exacerbation-
free during the study, and all children in the placebo group had at
least one exacerbation (Masekela 2013).
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Hospitalisations
One study of azithromycinwith 89 children showedno evidence of
a reduction in numbers of children hospitalised for exacerbations
between study groups (OR 0.28, 95% CI 0.07 to 1.11; Analysis
3.1; low-quality evidence), although again these results should be
interpretedwith caution owing to the low event rate (Valery 2013).
Serious adverse events
One study of azithromycin with 89 children reported serious ad-
verse events (Valery 2013), showing no differences between groups
in the number of children experiencing at least one event (OR
0.43, 95% CI 0.17 to 1.05; Analysis 3.2; low-quality evidence).
The majority of the serious adverse events related either to an ex-
acerbation or an investigation related to bronchiectasis (e.g., bron-
choscopy).
Secondary outcomes
Sputum volume and purulence
One study of roxithromycin with 25 children reported a reduction
in sputum purulence score with the intervention (MD -0.78, 95%
CI -1.32 to -0.24; Analysis 3.3) (Koh 1997).
Measures of lung function
Forced expiratory volume in one second (FEV1)
A meta-analysis of two studies with 65 participants showed no
evidence of benefit from azithromycin or roxithromycin in FEV1
expressed as percent of predicted by the end of the study (MD
1.73, 95% CI -3.32 to 6.78; Analysis 3.4) (Koh 1997; Valery
2013). Removing the study, which had unclear risk of bias for
sequence generation and allocation concealment from the meta-
analysis, had little impact on the treatment effect (MD 3.70, 95%
CI -5.99 to 13.39) (Koh 1997). Another study of erythromycin
(875 < 15 kg > 1750 mg/week for 52 weeks) with 42 children who
hadHIV and were all receiving highly active antiretroviral therapy
(HAART) reported no difference in FEV1 % predicted between
groups at the end of the study (MD 5.50, 95% CI -7.26 to 18.26)
(Masekela 2013).
Forced vital capacity (FVC)
Masekela 2013 reported no significant difference in FVC % pre-
dicted between groups at the end of the study (MD 5.00, 95% CI
-5.61 to 15.61).
Systemic markers of infection
One erythromycin study (875 mg < 15 kg > 1750 mg/week for
52 weeks) of 42 children with HIV who were receiving HAART
reported no differences in CRP levels between groups (MD 1.60,
95% CI -38.38 to 41.58) (Masekela 2013).
Adverse events
One study of azithromycin (30 mg/kg/week for 24 months) in 89
participants reported no differences between study groups in the
numbers of children experiencing adverse events (OR 0.78, 95%
CI 0.33 to 1.83; Analysis 3.5) (Valery 2013).
All-cause mortality
Masekela 2013 reported the death of one randomised participant
but did not state the study group to which that participant had
been assigned (low-quality evidence).
Emergence of resistance to antibiotics
One study of azithromycin in 89 children reported an increase
in macrolide-resistant bacteria (OR 7.13, 95% CI 2.13 to 23.79;
Analysis 3.6), an increase in resistance to Streptococcus pneumoniae
(OR 13.20, 95%CI 1.61 to 108.19; Analysis 3.7), and an increase
in resistance to Staphylococcus aureus (OR 4.16, 95% CI 1.06 to
16.32; Analysis 3.8) with macrolides compared with placebo (
Valery 2013).
The included studies did not report our other secondary outcomes:
exercise capacity and health-related quality of life.
Macrolide versus no intervention: children
Primary outcomes
The included study did not report our primary outcomes: exacer-
bations, hospitalisations, and adverse and serious adverse events.
Secondary outcomes
Sputum volume and purulence
One study of clarithromycin with 34 children (105 mg/week 3
months) reported a significantly greater reduction in sputum vol-
ume with macrolides compared with placebo (P = 0.0001) but did
not report exact values for each group (Yalcin 2006).
Measures of lung function
Yalcin 2006 also reported no differences in FEV1 between groups
but did not report exact values and significance levels.
Mortality
Yalcin 2006 reported no deaths (low-quality evidence).
The included study did not report our other secondary outcomes:
systemic markers of infection, adverse events, resistance to antibi-
otics, exercise capacity, and quality of life.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Macrolides compared with no intervention for adults with bronchiectasis
Patient or population: adults with bronchiectasis
Setting: outpat ient clinics in China and Spain
Intervention: macrolides
Comparison: no intervent ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no interven-
tion
Risk with macrolides
≥ 1 exacerbat ion
Follow-up: 6 months
Study populat ion OR 0.31
(0.08 to 1.15)
43
(1 RCT)
⊕⊕⊕©
MODERATEa
Roxithromycin (1050
mg/ week for 6 months)
762 per 1000 498 per 1000
(204 to 786)
Hospitalisat ions - not
reported
- - - - -
Serious adverse events
- not reported
- - - - -
Mortality
Follow-up: range 3
months to 6 months
No deaths in two trials, although in 1 study
(azithromycin), 6 part icipants were lost to follow-
up
not est imable 88
(2 RCTs)
⊕©©©
VERY LOWa,b,c
1 study azithromycin
(750 mg/ week for 3
months)
1 study roxithromycin
(1050 mg/ week for 6
months)
QoL SGRQ: endpoint to-
tal score
Scale f rom 0 to 100
Follow-up: 6 months
Mean SGRQ: endpoint
total score of 51.7
points
MD 8.81 lower (14.33
lower to 3.28 lower)
- 89
(2 RCT)
⊕⊕⊕©
MODERATEa
1 study roxithromycin
(1050 mg/ week for 6
months)
1 study roxithromycin
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(1050 mg/ week for 6
months)
QoL SGRQ: change in
total score
Scale f rom 0 to 100
Follow-up: 3 months
Mean SGRQ: change in
total score of 4.1
MD 12 lower
(21.61 lower to 2.39
lower)
- 30
(1 RCT)
⊕⊕⊕©
MODERATEa
Azithromycin (750 mg/
week for 3 months)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval;MD: mean dif ference; RCT : randomised controlled trial; RR: risk rat io; OR: odds rat io; QoL: quality of lif e; SGRQ: St. George’s Respiratory Quest ionnaire.
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOpen-label study (one point deducted in relat ion to design and implementat ion of available studies suggest ing likelihood of
bias).
bUnclear randomisat ion and study methods (one point deducted in relat ion to design and implementat ion of available studies
suggest ing likelihood of bias).
c6 part icipants in one study lost to follow-up and no further details reported (one point deducted in relat ion to design and
implementat ion of available studies suggest ing likelihood of bias).
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Macrolides compared with placebo for children with bronchiectasis
Patient or population: children with bronchiectasis
Setting: outpat ient clinics in Australia, New Zealand, and South Af rica
Intervention: macrolides
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with macrolides
Exacerbat ion f requency Number of exacerba-
t ions 195 (median: 4
range 0-14)
Number of exacerba-
t ions 104 (median: 2
range 0-9)
IRR 0.50 95%CI 0.35 to
0.71
89
(1 RCT)
⊕⊕©©
LOWa,b
Azithromycin (30 mg/
kg/ week for up to 24
months)
Hospitalisat ion: all-
cause
Follow-up: 24 months
205 per 1000 67 per 1000
(18 to 222)
OR 0.28
(0.07 to 1.11)
89
(1 RCT)
⊕⊕©©
LOWa,b
Azithromycin (30 mg/
kg/ week for 24 months)
Serious adverse events
Follow-up: 24 months
432 per 1000 246 per 1000
(114 to 444)
OR 0.43
(0.17 to 1.05)
89
(1 RCT)
⊕⊕©©
LOWa,b
Azithromycin (30 mg/
kg/ week for 24 months)
Mortality 1 child died but study group was not stated. - 42
(1 RCT)
⊕⊕©©
LOWc,d
Erythromycin (875 to
1750 mg/ kg/ week for
52 weeks)
Quality of lif e not re-
ported
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IRR: incidence rate rat io; OR: odds rat io; RCT : randomised controlled trial; RR: risk rat io.
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GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWide conf idence interval that includes 1 (no dif ference) (one point deducted for imprecision).
bLow event rates and low numbers (one point deducted in relat ion to design and implementat ion of available studies
suggest ing likelihood of bias).
cUnclear information on randomisat ion, blinding, and other study methods (one point deducted in relat ion to design and
implementat ion of available studies suggest ing likelihood of bias).
dNo information on part icipants lost to follow-up (one point deducted in relat ion to design and implementat ion of available
studies suggest ing likelihood of bias).
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Macrolides compared with no intervention for children with bronchiectasis
Patient or population: children with bronchiectasis
Setting: outpat ient clinic in Turkey
Intervention: macrolides
Comparison: no intervent ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no interven-
tion
Risk with macrolides
Exacerbat ions - not re-
ported
- - - - -
Hospitalisat ion - not re-
ported
- - - - -
Serious adverse events
- not reported
- - - - -
Mortality
Follow-up: 3 months
0 per 1000 0 per 1000
(0 to 0)
not est imable 34
(1 RCT)
⊕⊕©©
LOWa,b
Clarithromycin
(105 mg/ kg/ week for 3
months)
Quality of lif e - not re-
ported
- - - - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT : randomised controlled trial.
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GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a Insuf f icient information on study methods and procedures (one point deducted in relat ion to design and implementat ion of
available studies suggest ing likelihood of bias).
bNot blinded (one point deducted in relat ion to design and implementat ion of available studies suggest ing likelihood of bias).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
Fifteen randomised trials met the inclusion criteria for this system-
atic review; 11 studies included adult participants only (Altenburg
2013; Asintam 2012; Cymbala 2005; Diego 2013; Juthong 2011;
Liu 2012; Liu 2014; Lourdesamy 2014; Sadigov 2013; Serisier
2013; Wong 2012), and in four studies (Koh 1997; Masekela
2013; Valery 2013; Yalcin 2006), the participants were children.
Considerable clinical heterogeneity was evident on a range of other
factors, including four different types of macrolides, doses rang-
ing from 750 mg/week to 3500 mg/week with regimens varying
from twice daily to once a week, intervention duration ranging
from eight weeks to 24 months, and background therapies admin-
istered to all groups in two studies. None of the included studies
compared one type of macrolide versus another or versus a non-
macrolide antibiotic.
Evidence shows a reduction in exacerbations seen in our aggrega-
tion of data from four adult studies, including Altenburg 2013,
Sadigov 2013 Serisier 2013 and Wong 2012, and from one study
of children - Valery 2013 - comparing macrolides with placebo,
and we used GRADE criteria to assess the quality of this evi-
dence as moderate. Most of these studies (with the exception of
Serisier 2013) used azithromycin. Masekela 2013 reported no re-
duction in the number of exacerbations over 52 weeks with ery-
thromycin compared with placebo. This study was carried out in
South African children with HIV who were receiving antiretrovi-
rals and showed varying degrees of HIV virological suppression.
The specifics of this population make it difficult to generalise the
findings of Masekela 2013 to individuals with bronchiectasis in
less specialised circumstances. Studies comparing macrolides with
no intervention were insufficient to establish clear effects. For hos-
pitalisations, data show no evidence of benefit with azithromycin
based on aggregation of data from two adult studies (Altenburg
2013; Lourdesamy 2014), alongwith one study of children (Valery
2013), and on evidence of low quality. We are unable to draw
any conclusions on which macrolides may be most beneficial, as
data were not available for all of our planned subgroups. Available
low-quality evidence from four adult studies, including Altenburg
2013 Lourdesamy 2014 Serisier 2013 and Wong 2012, and from
one study of children - Valery 2013 - suggests that participants re-
ceiving macrolides experienced more adverse events. We are again
unable to draw clear conclusions regarding the effectiveness of dif-
ferent macrolides, as four of the five studies used azithromycin.
Studies comparing macrolides with no intervention did not report
this outcome.
Overall our review provides promising, but inconclusive, results
for our three predefined primary outcomes, but on the basis of
currently available evidence, we are unable to present robust con-
clusions.
For our secondary outcomes, aggregated data from six studies
comparing macrolides against placebo and yielding moderate- to
low-quality evidence (Altenburg 2013; Asintam 2012; Juthong
2011; Lourdesamy 2014; Serisier 2013; Wong 2012) indicate
that macrolides have a positive impact on health-related quality
of life, as measured by St. George’s Respiratory Questionnaire
(SGRQ). Similarly, three studies comparing macrolides with no
treatment showed improved quality of life with the intervention
(Diego 2013; Liu 2012; Liu 2014). Data on sputum volume and
purulence, measures of lung function, markers of infection, and
demonstrated exercise capacity provided no indication of bene-
fit from macrolides in adults. One of the largest adult studies of
erythromycin provided limited evidence of increased resistance to
macrolides (Serisier 2013).
None of the four children’s studies measured quality of life.
Macrolides were associated with improved sputum characteristics
in two children’s studies (Koh 1997; Yalcin 2006). Studies with
children provided no evidence of benefit frommacrolides in terms
of measures of lung function, markers of infection, or demon-
strated exercise capacity. One study of azithromycin with children
provided limited evidence of increased resistance to macrolides
(Valery 2013).
Evidence of moderate to very low quality from the 15 included
studies provided no indication of a higher mortality rate with
macrolides.
In relation to our predefined secondary outcomes, health-related
quality of life data further strengthen the impression noted in our
primary outcomes that this interventionmerits further exploration
in high-quality clinical trials.
Overall completeness and applicability of
evidence
We have identified studies of macrolides in bronchiectasis report-
ing exacerbation and hospitalisation rates. Data for planned sec-
ondary outcomes, particularly adverse effects, are lacking. Our
findings are based on studies totalling 690 adults and 190 children.
Investigators used several different macrolide antibiotics (azithro-
mycin, erythromycin, roxithromycin, and clarithromycin) in these
populations in a variety of international settings. This breadth en-
hances the generalisability of findings but may conceal an advan-
tage of, for example, one macrolide over another or use in adults
over use in children, as none of the included studies reported di-
rect comparisons between different macrolides or between adults
and children. Small and short-term studies mean that we may not
detect small but clinically important increases in absolute risk for
serious adverse events. Such adverse events, including mortality as
reported in Ray 2012 and hearing loss as described in Albert 2011,
have been reported in larger studies of macrolides for indications
other than bronchiectasis. Although this review provides limited
evidence of benefit associated with macrolide antibiotics, their rel-
ative benefit compared with benefit derived from other types of
antibiotics remains unknown, as we did not identify any studies
that included these comparisons.
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Apart from Altenburg 2013, Juthong 2011, Serisier 2013, Wong
2012, and Valery 2013, we found a lack of information on micro-
bial resistance associated with the macrolides used in the reports
of included studies. No studies were designed to evaluate changes
in resistance patterns in the wider community.
Quality of the evidence
The overall quality of studies included in this review ranges from
very low tomoderate for outcomes included in theGRADE assess-
ment. From adult studies comparing macrolides versus placebo,
the evidence for frequency of exacerbations and mortality from all
causes is of moderate quality owing to imprecision of the effect
(limited to azithromycin). Evidence for hospitalisations, serious
adverse events, and quality of life was of low quality owing to study
design limitations (unclear study methods, open-label approach)
and imprecision of the effect (few studies and wide confidence
intervals), which resulted in downgrading of the quality of out-
comes. Evidence for all-cause mortality is of poor quality owing
to unclear reporting and losses to follow-up. From adult studies
that compared macrolides versus no intervention, the evidence for
frequency of exacerbations and quality of life as assessed by the
SGRQ is of moderate quality owing to limitations in study de-
sign (open-label study) and imprecision of the effect (few studies
and no confidence intervals). The quality of evidence for mortal-
ity from all causes is very low owing to serious design limitations
(open-label study, unclear study methods) and inadequate report-
ing of participants lost to follow-up.
Studies that compared macrolides versus placebo in children have
provided low-quality evidence on frequency of exacerbations, hos-
pitalisations, serious adverse events, and mortality owing to de-
sign limitations (unclear methods), imprecision (wide confidence
intervals and low event rates), and no information on participants
lost to follow-up. The single small study that comparedmacrolides
versus no intervention in children provided low-quality evidence
on mortality from all causes owing to insufficient information on
trial methods and imprecision.
We judged only four of our 15 included studies - three with adults
and one with children - as having low risk of bias across all do-
mains. Selection bias was unclear in nearly half of the included
studies owing to lack of detailed reporting on random sequence
generation and allocation concealment. Most studies blinded par-
ticipants to group allocation, but several studies described investi-
gator blinding in a way that was unclear, and most trials reported
blinding of outcome assessment that was also unclear. None of
the included studies had high risk of attrition or reporting bias,
although some studies provided no information on participants
who were lost to follow-up. Furthermore, only six studies explic-
itly reported the role of funders in the trial; six studies registered
their protocol on trial registries; and eight studies reported that
investigators performed a formal sample size calculation before the
start of the trial.
Potential biases in the review process
Weused a comprehensive systematic search, conducted by a highly
experienced information specialist, to identify potentially eligi-
ble studies. We searched multiple resources, including electronic
databases, journals, conference proceedings, reference lists of in-
cluded studies, citations of included studies, and trial registries.
Nevertheless, we recognise the possibility of publication bias in
this review that could either overestimate or underestimate effects
of the intervention in terms of the different outcomes included
in the review. Trials showing no, or negative, effects are less likely
to be offered for publication, and if offered are less likely to be
accepted, resulting in a biased set of data available for review. As
we included only a few studies for each outcome, we were unable
to assess the presence of publication bias through formal testing.
Furthermore, some papersmay have beenmisclassified as not eligi-
ble for inclusion in this review. Two review authors independently
assessed all studies, and a third review author verified the data;
we are confident that we assessed studies excluded from analyses
on the basis of consistent and appropriate criteria. For some full-
text reports, it is possible that we could have entered some data
into analyses incorrectly, although we double-checked all data to
attempt to avoid extraction errors.
We contacted the investigators of three included studies based on
conference proceedings that were available as an abstract, to obtain
study characteristics and other numerical outcome data. Although
we received responses from all of these investigators, we found that
data from only two studies were provided. The same investiga-
tor was involved in both of these studies, which were conducted
in similar settings and used similar interventions. Owing to the
small number of included studies, we did not explore the impact
of excluding studies with missing outcome data in the overall as-
sessment of results by performing a sensitivity analysis. Finally,
data were insufficient to permit all planned subgroup analyses, so
we included only types of antibiotics, which we considered most
clinically important.
Agreements and disagreements with other
studies or reviews
Major findings of the present review are largely in agreement with
the results of previously published meta-analyses of the impact
of macrolides on outcomes in bronchiectasis (Gao 2014), which
have shown a reduced frequency of exacerbations, improved lung
function, and improved quality of life with prolonged macrolide
treatment. Differences in effect size between our present review
and these previously published meta-analyses reflect differences
in the inclusion and exclusion criteria of studies, as well as the
inclusion of some recent studies. In general, the strict methods
applied in the present review have resulted in pooling of fewer
studies and therefore more precise effect estimates.
The three largest macrolide trials have the longest duration of
follow-up and are concordant with overall results of the meta-
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analysis, with each demonstrating benefit in terms of frequency of
and/or time to first exacerbation (Altenburg 2013; Serisier 2013;
Wong 2012). It is striking that all three studies are of high quality
(Figure 4).
The benefit in terms of exacerbations was largely attributable to
azithromycin. This should not be taken to indicate that azithro-
mycin is superior to other macrolides because the characteristics
of participants in the BLESS study of erythromycin were different
from those of participants enrolled in azithromycin studies. Our
analysis is not designed to determine whether the drug or the pa-
tient cohort is responsible for the apparent differential effect.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review includes 11 studies with 690 adults and four stud-
ies with 190 children. Long-term macrolide therapy is an option
for patients with bronchiectasis with the aim of reducing the rate
of exacerbations and improving quality of life. Supporting evi-
dence is derived mainly from studies of azithromycin, rather than
other macrolides, and predominantly in adults rather than in chil-
dren. However,macrolides should be used with caution, as limited
data support an increase in microbial resistance with macrolides.
Macrolides have been associated with excessive risk of cardiovas-
cular death and other serious adverse events in populations other
than individuals with bronchiectasis (Ray 2012), and available
data cannot exclude a similar risk in patients with bronchiectasis.
The presence of non-tuberculous mycobacteria (NTM) should be
identified in all patients before long-term macrolide therapy is be-
gun.
Implications for research
The present review highlights several outstanding questions on
long-term macrolide treatment in clinical practice. Although
macrolides significantly reduced exacerbations, studies used dif-
ferent macrolide drugs at different doses. As a result, we are unable
to recommend the most appropriate agent, dose, or administra-
tion schedule (daily vs intermittent) for long-term therapy. Doses
ranging from 250 mg three times per week to 500 mg daily have
been reported in clinical practice.
The European Bronchiectasis Network (EMBARC) recently pub-
lished a series of research priorities, which included several re-
lated to macrolide treatment. Recognising the limitations of exist-
ing data, EMBARC recommended longer-term studies to evaluate
the development of antibiotic resistance as well as long-term sa-
fety. Further studies conducted to determine whether macrolides
should be administered continuously or in a cyclical pattern (as
during the winter, when exacerbations occur more frequently)
would help guide clinical practice. The optimal patient popula-
tion to benefit from macrolides has not been identified, as each of
the macrolide studies was too small to allow meaningful subgroup
or ’responder’ analyses. It is unclear whether macrolide therapy is
suitable for all patients with bronchiectasis, and macrolides have
important side effects, including the risk of inducing antibiotic
resistance; thus, EMBARC has recommended further research to
target these topics more effectively.
Existing studies and meta-analyses have largely taken the view that
macrolide efficacy in bronchiectasis has been proven, and that ad-
ditional large studies are unnecessary. Our results suggest that sub-
stantial uncertainties about macrolide efficacy remain, particularly
with regard to improvements in quality of life and lung function,
as well as impact on antimicrobial resistance. In addition, the rel-
ative benefits of macrolides compared with those of other types of
antibiotics are unknown, as we did not identify any studies that
included these comparisons. Our analysis suggests that additional
large, randomised, placebo controlled trials should be performed
to confirm the efficacy and safety of macrolides.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Altenburg 2013
Methods Aims: to investigate whether 1 year of long-term low-dose macrolide treatment added
to standard therapy is effective in reducing exacerbation frequency in patients with non-
CF bronchiectasis
Design: randomised, double-blind, placebo-controlled trial
Total study duration: 30 months
Number of study centres and locations: 14, Netherlands
Study setting: outpatient clinics
Methods of recruitment: outpatient clinics at each study centre by the pulmonary
physician or the study investigator
Withdrawals: 1 in each group owing to adverse events
Study start/end dates: April 2008/September 2010
Analysis by intent-to-treat: yes
Participants 83 adults randomised
Inclusion criteria: individuals 18 years of age or older with non-CF bronchiectasis
diagnosed by plain bronchography or high-resolution computed tomography,≥ 3 lower
respiratory tract infections (LRTIs) treated with oral or intravenous antibiotics in the
preceding year, and ≥ 1 sputum culture yielding ≥ 1 bacterial respiratory pathogen in
the preceding year
Exclusion criteria: prolonged (> 4 weeks) macrolide therapy during the previous 3
months, oral or intravenous corticosteroids within 30 days of screening, or any antimi-
crobial treatment for an LRTI in the previous 2 weeks
Mean age: intervention group: 59.9 years; control group: 64.6 years
Gender: intervention group: 25 females, 18 males; control group: 28 females, 12 males
Bronchiectasis diagnosis: plain bronchography or HRCT
Severity of condition: not reported
Baseline lung function: FEV1 (% predicted): intervention group: 77.7, control group:
82.7; FVC (% predicted): intervention group: 91.9, control group: 98.5
Smoking history: 2% current, 44% former, 54% never
Baseline imbalances: no statistically significant differences between groups
Interventions Intervention group: azithromycin (n = 43)
Dose: 250 mg; delivery mode: oral; frequency: 1/d; duration: 52 weeks
Control group: placebo (n = 40)
Placebo tablets indistinguishable from azithromycin were manufactured by a licensed
trial pharmacy
Adherence: empty blister-pack count: intervention group: 96.5%; control group: 98%
Run-in phase: following randomisation, participants observed for clinical stability for
2 weeks
Run-out phase: variable run-out period of ≥ 90 days after 1 year of intervention
Outcomes Primary: number of infectious exacerbations, defined as an increase in respiratory symp-
toms requiring antibiotic treatment. Two types of exacerbations - a protocol-defined
exacerbation (PDE) and a non-PDE
Secondary: lung function, CRP level, WBC count, microbiological evaluation, LRTI,
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Altenburg 2013 (Continued)
HRQoL, and adverse events
Post hoc analysis: time to a first exacerbation
Notes Power calculation: assuming that azithromycin would reduce the number of exacerba-
tions by at least one-third, a 1-sided significance level of P = 0.05, with 80% power and
estimated 20% dropout = total of 90 patients, for 36 per group
Trial registration: clinicaltrials.gov Identifier: NCT00415350
Conflicts of interest: Dr. Boersma reported serving on an advisory board, and receiving
payment from Pfizer, for an educational presentation. No other review authors reported
COIs
Funders: Dr. Altenberg and Dr. Boersma were supported by a research grant from
the Forest Medical School, an independent scientific institution based in the Alkmaar
Medical Centre. The study was also supported by an unrestricted research grant from
GlaxoSmithKline, and Teva Netherlands supplied the azithromycin tablets
Role of the sponsors: Funders had no role in the design and conduct of the study;
collection, analysis, and interpretation of data; or preparation, review, or approval of the
manuscript
Ethical approval: yes
Conclusions: Macrolide maintenance therapy was effective in reducing exacerbations
in patients with non-CF bronchiectasis. In this trial, azithromycin treatment resulted in
improved lung function and better quality of life but involved an increase in gastroin-
testinal adverse effects and high rates of macrolide resistance
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted block randomisation was per-
formed centrally with equally sized blocks
of 10
Allocation concealment (selection bias) Low risk Placebo and azithromycin tablets were pro-
vided in identical, individually numbered
boxes, with each box containing a year’s
supply of study medication for 1 partici-
pant.Numbers on the boxesmatched treat-
ment allocation, in accordance with a com-
puter-generated allocation sequence that
was kept in a safe place in the pharmacy
providing the study medication
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants were seen by the inves-
tigator and were sequentially assigned a
subject identification code through dou-
ble-blinded allocation to azithromycin or
placebo treatment. Placebo tablets were in-
distinguishable from azithromycin tablets
with respect to appearance, feel, and taste
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Altenburg 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Attending physicians reporting study out-
comes were blinded to group allocation. It
is unlikely that blinding was ineffective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Balanced between groups with similar rea-
sons for withdrawal
Selective reporting (reporting bias) Low risk Study protocol prepublished and all pre-
specified outcomes reported
Other bias Low risk None identified
Asintam 2012
Methods Aims: to determine whether roxithromycin would alter clinical outcomes
Design: randomised, double-blind, placebo-controlled trial
Total study duration: 6 months
Number of study centres and locations: 1, Thailand
Study setting: outpatient department, Songklanagarind Hospital
Methods of recruitment: unclear
Withdrawals: intervention group: 4, control group: 5
Study start/end dates: March 2011/September 2011
Analysis by intent-to-treat: unclear
Participants 30 adults were randomised.
Inclusion criteria: adults aged 15 to75 years; symptomatic patients, with total symptoms
score* ≥ 2 per day; stable clinical state; absence of deterioration in cough, dyspnoea,
wheezing, fever, chest pain at least 2 weeks before randomisation
Exclusion criteria: adverse drug reaction to macrolides; recent exacerbation within 2
weeks before randomisation; history ofmacrolide therapywithin 2weeks before randomi-
sation; active malignancy and end-stage disease, such as chronic heart failure, chronic
renal failure, and cirrhosis; inability of patients to perform lung function tests due to
haemoptysis, AFB positivity, aortic aneurysm, and unstable angina; women who were
lactating
Mean age: intervention group: 67 years; control group: 64 years
Gender: intervention group: 9 women, 6 men; control group: 14 women, 1 man
Bronchiectasis diagnosis: HRCT
Severity of condition: intervention group: 13 (range 9-19); control group: 12 (range 5-
19) (Bhalla)
Baseline lung function: FEV1 (% predicted): intervention group: 53.5 ± 13.9; control
group: 61.7 ± 19.2; FVC (% predicted): intervention group: 65.4 ± 20; control group:
66.9 ± 14.3
Smoking history: 20% former, 80% never; smoking history in pack-years: intervention
group: 6.7 years; control group: 0.7 years
Baseline imbalances: no statistically significant differences between groups
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Asintam 2012 (Continued)
Interventions Intervention group: roxithromycin (n = 15)
Dose: 300 mg; delivery mode: oral; frequency: once daily; duration: 12 weeks
Control group: placebo (n = 15)
Co-interventions: mucolytic drugs (93%), SABA (73%), theophylline (63%), and a
combination of LABA/ICS (47%)
Adherence: not reported
Run-in phase: not reported
Run-out phase: 12-week wash
Outcomes Primary: quality of life (SGRQ)
Secondary: exacerbations, sputum volume, pulmonary function tests
Post hoc analysis: not reported
Notes Power calculation: estimated 61 patients needed to detect an increment in SGRQ scores
of 12% with roxithromycin as compared with placebo with statistical power (1 minus
the β value) of 80%, allowing for a type I (α) error of 0.05
Trial registration: not reported
Conflicts of interest: not reported
Funders: not reported
Role of the sponsors: not reported
Ethical approval: yes
Conclusions: 12-week roxithromycin 300 mg once daily in symptomatic stable
bronchiectatic patients; did not show significant improvement in QoL by SGRQ scores,
reduced sputum volume, or improved lung function
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Eligible subjects were randomized (1:1)
into the treatment and control groups by
block of four randomization method”; in-
sufficient detail
Allocation concealment (selection bias) Unclear risk “30 patients were randomly allocated”; in-
sufficient detail
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient detail
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient detail
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 9 patients withdrew (30%), but no further
details were reported
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Selective reporting (reporting bias) Unclear risk The protocol was not prespecified.
Other bias Unclear risk Details of funding sources were not re-
ported.
Cymbala 2005
Methods Aims: to determine whether long-term, low-dose azithromycin would improve pul-
monary function and decrease incidences of infection and exacerbation
Design: open-label, cross-over, randomised controlled (no intervention) trial
Total study duration: 12 months
Number of study centres and location: 1, USA
Study setting: outpatient clinic
Methods of recruitment: unclear
Withdrawals: 1, who provided insufficient data for analysis
Study start/end dates: January 2001/December 2001
Analysis by intent-to-treat: no
Participants 12 adults were randomised.
Inclusion criteria: patients aged > 18 years with a clinical diagnosis of bronchiectasis
confirmed by HRCT, demonstrating airways larger than accompanying vessels
Exclusion criteria: patients with a history of serious intolerance, allergy, or sensitivity
to azithromycin or macrolides. In addition, if the investigator believed that the patient may
not be able to follow instructions, the patient was excluded.
Mean age: 70.8; SD 9.7 years
Gender: 6 women, 5 men
Bronchiectasis diagnosis: HRCT
Severity of condition: not reported
Baseline lung function (intervention group, control group): FEV1 (% predicted):
65.3, SD 15.1; FVC (% predicted): 48.5, SD 19.9
Smoking history: present or ex-smoker: 8; never: 3
Baseline imbalances: not reported
Interventions Intervention group: azithromycin plus usual medications (n = 8)
Dose: 500 mg; delivery mode: oral; frequency: 2/week (Monday and Thursday); dura-
tion: 6 months
If participants complained of intolerable adverse events from the azithromycin regimen
but wanted to continue in the study, their azithromycin regimen was reduced to 250 mg
orally every Monday, Wednesday, and Friday
Control group: usual medications alone (n = 3)
Adherence: 85% to 108% on azithromycin (1 person took an additional dose)
Run-in phase: 1-month washout in participants who received azithromycin first
Run-out phase: unclear
Outcomes Primary: did not state which of the outcomes below was primary
Secondary: pulmonary function tests (diary card), PF measurements, 24-hour sputum
volume
Post-hoc analysis: unclear
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Cymbala 2005 (Continued)
Notes Power calculation:By a paired t-lest power calculation, the original proposed sample size
of 30 participants would have provided 92.5% power at an alpha of 0.1 to identify a 50%
change in 24-hour sputum volume. However, only 11 of the 12 enrolled participants
completed the study; therefore, the power to identify the same extent of change in 24-
hour sputum volume fell to 56%
Trial registration: not reported
Conflicts of interest: no conflicts of interest for 6 study authors. One had received
payments from several pharmaceutical companies including Pfizer, Bayer, Abbott, and
Bristol Myers Squibb
Funders: The first year of the study was unfunded, although investigators received
donations of study medication from local sales representatives. In the second year, a small
unrestricted stipend was received from the manufacturer of azithromycin that covered
participant incidentals (i.e. travel expenses, extra pulmonary function tests only)
Role of the sponsors: unclear
Ethical approval: yes
Conclusions: The results of this pilot study support past data regarding probable
disease-modifying benefits of long-term macrolide use in the treatment of individu-
als with chronic inflammatory pulmonary disorders. Long- term therapy with twice-
weekly azithromycin was well tolerated and may provide added benefit for patients with
bronchiectasis without the adverse effect of immunosuppression, which is demonstrated
with corticosteroids. Given that significant findings were identified in a study with such
a limited sample size, additional large-scale trials are warranted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
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Other bias High risk “Because of the randomization schedule
and less than expected numbers at enrol-
ment, the distribution of patients between
the two study phases they received first was
heavily biased, with 8 of II (73%) patients
receiving the azithromycin phase first”
The randomisation schedule was ineffec-
tive, with most receiving the active inter-
vention in the first phase
Diego 2013
Methods Aims: to explore the effect of long-term therapy with azithromycin on airway oxidative
stress markers in exhaled breath condensate (EBC)
Design: open-label, randomised controlled (no intervention) trial
Total study duration: 12 months
Number of study centres and location: 1, Spain
Study setting: outpatient clinic
Methods of recruitment: invited patients with confirmed diagnosis of bronchiectasis
attending clinic at University Hospital La Fe
Withdrawals: 6. Numbers per study group not reported
Study start/end date: 2005
Analysis by intent-to-treat: no
Participants 36 adults were randomised.
Inclusion criteria: stable, without change in medication or symptoms, emergency de-
partment visits or hospitalisations in the previous 4 weeks
Exclusion criteria: positive sweat test for CF, bronchiectasis secondary toCF, pulmonary
surgical processes, immunodeficiency secondary to HIV, malignancy, common variable
immunodeficiency, emphysema, allergic bronchopulmonary aspergillosis or diffuse in-
terstitial pulmonary disease, intolerance to macrolides, severe liver disease
Mean age: 58 years; intervention group: 57 years; control group: 61 years
Gender: intervention group: 9 women, 7 men; control group: 7 women, 7 men
Bronchiectasis diagnosis: clinical data and HRCT
Severity of condition: intervention group: 22; control group: 31 (Bhalla)
Baseline lung function: FEV1 (% predicted): intervention group: 56, SD 6; control
group: 58, SD 7
Smoking history: not reported
Baseline imbalances: no statistically significant differences between groups
Interventions Intervention group: azithromycin plus usual care (n = 16)
Dose: 250 mg; delivery mode: oral; frequency: 3/week; duration: 3 months
Control group: usual care alone (n = 14)
Participants in both groups continued taking their habitual treatment to the same doses,
including inhaled steroids, bronchodilators, mucolytic therapy, and physiotherapy. In
cases of severe exacerbations, steroids or antibiotics were recommended
Adherence: not reported
Run-in phase: unclear
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Run-out phase: unclear
Outcomes Primary: changes in airway oxidative stress markers (FeNO, 8-isoprostane, nitrites
(NO2), and nitrates (NO3))
Secondary: changes in lung function (FVC, FEV1 (pre- and post-BD), FEV1/FVC,
total lung capacity, colour and volume of sputum, number of exacerbations, hospital
admissions, functional capacity, health-related quality of life
Post hoc analysis: colonised vs not colonised with Pseudomonas aeruginosa
Notes Power calculation: based on expected 10% difference in FeNO between groups with
90% power and 5% statistical significance
Trial registration: clinicaltrials.gov: NTC01463371
Conflicts of interest: not reported
Funders: Fundacion Valenciana de Neumologia
Role of the sponsors: not reported
Ethical approval: yes
Conclusions: 3-month treatment with azithromycin; clinical benefit in patients with
non-CF bronchiectasis but no effect on airway oxidative stress markers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study investigators were blinded to group
allocation, but this was an open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Six participants were lost to follow-up. No
reasons for missing data were provided
Selective reporting (reporting bias) Low risk Study protocol was published and all pre-
specified (primary and secondary) out-
comes were reported
Other bias Low risk None identified
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Methods Aims: to investigate the efficacy of once-daily roxithromycin for improving clinical out-
comes
Design: double-blind, randomised, placebo-controlled trial
Total study duration: 6 months
Number of study centres and location: 1, Thailand
Study setting: outpatient department, Songklanagarind Hospital
Methods of recruitment: not reported
Withdrawals: none
Study start/end dates: June 2010/November 2010
Analysis by intent-to-treat: yes
Participants 26 adults were randomised.
Inclusion criteria: aged 18 years and above, diagnosis of bronchiectasis, symptomatic
bronchiectasis
Exclusion criteria: macrolides in previous year, exacerbation of bronchiectasis in pre-
vious 3 months, allergy to macrolides, active malignancy, active or recent pulmonary
infection within 3 months, pregnancy
Mean age: intervention group: 55 years; control group: 60 years
Gender: intervention group: 4 women, 8 men; control group: 8 women, 6 men
Bronchiectasis diagnosis: chest radiograph and HRCT; diagnosis confirmed by pul-
monologist
Severity of condition: described as “severe”
Baseline lung function: FEV1 (L): intervention group: 1.53 ± 0.62; control group: 1.
31 ± 0.44; FVC (L): intervention group: 2.27 ± 0.79; control group: 1.98 ± 0.55
Smoking history: present 2 (8%),former: 6 (23%), never 18 (69%)
Baseline imbalances: no statistically significant differences between groups
Interventions Intervention group: roxithromycin (n = 12)
Dose: 300 mg; delivery mode: oral; frequency: once daily; duration: 8 weeks
Control group: placebo (n = 14)
Adherence: not reported
Run-in phase: not reported
Run-out phase: not reported
Outcomes Primary: symptoms scores, pulmonary function tests (FEV1 L, FVC L)
Secondary: safety, tolerability, drug resistance
Post hoc analysis: not reported
Notes Power calculation: not reported
Trial registration: unclear
Conflicts of interest: not stated
Funders: Faculty and Hospital Fund for Research, Songklanagarind Hospital
Role of the sponsors: not reported
Ethical approval: not reported
Conclusions:Once-daily roxithromycin showed benefit for clinical outcomes as well as
quality of life. Larger studies on the effects of macrolide in bronchiectasis treatment with
longer follow-up times should be done
Risk of bias
46Macrolide antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Juthong 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind effectiveness was confirmed
by contact with trial authors
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals were reported.
Selective reporting (reporting bias) Unclear risk Informaiton was insufficient to permit
judgement of ’low risk’ or ’high risk’
Other bias Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Koh 1997
Methods Aims: to determine whether roxithromycin can reduce the degree of airway responsive-
ness in bronchiectasis
Design: double-blind, randomised, placebo-controlled trial
Total study duration: 12 weeks
Number of study centres and location: 1, South Korea
Study setting: outpatient clinic, Seoul National University Hospital
Methods of recruitment: selected from the outpatient clinic list
Withdrawals: 2 (1 in each group) removed by investigators owing to non-compliance
Study start/end dates: October 1995/February 1996
Analysis by intent-to-treat: no
Participants 25 children were randomised.
Inclusion criteria: increased airway responsiveness (defined as a provocative concentra-
tion of methacholine causing a 20% fall in FEV1 (PC20) < 25 mg/mL evaluated by the
dosimeter method
Exclusion criteria: not explicitly stated but patients with cystic fibrosis, humoral im-
mune deficiency, bronchopulmonary aspergillosis, excluded; also, those who had taken
antibiotics or corticosteroids or who had an upper respiratory tract infection in the past
month
Mean age: intervention group: 13.3 years; control group: 12.9 years
Gender: intervention group: 6 girls, 7 boys; control group: 5 girls, 7 boys
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Bronchiectasis diagnosis: clinical features; confirmed by computed tomography, with
bronchography when necessary
Baseline lung function: FEV1 (% predicted): intervention group: 83 ± 6; control group:
84 ± 7
Smoking history: not applicable
Severity of condition: not reported
Baseline imbalances: 3 asthmatic patients in the intervention group and 4 in the control
group. In the initial methacholine challenge test, 3 participants in the intervention group
and 2 in the control group did not attain amaximal response plateau.No other significant
differences were noted at baseline
Interventions Intervention group: roxithromycin (n = 13)
Dose: 4 mg/kg; delivery mode: oral; frequency: 2/d; duration: 12 weeks
Control group: placebo (n = 12)
Adherence: used packets or drug sachets monitored for compliance; 2 participants with-
drew owing to non-compliance
Run-in phase: not reported
Run-out phase: not reported
Outcomes Primary: unclear which of the outcomes below were primary
Secondary: FEV1, sputum colour (sputum purulence score), sputum - polymorphonu-
clear leucocyte (PMN) (sputum leucocyte score)
Post hoc analysis: unclear
Notes Power calculation: not reported
Trial registration: not reported
Conflicts of interest: not reported
Funders: Seoul National University Hospital Research Fund
Role of the sponsors: not reported
Ethical approval: yes
Conclusions: Roxithromycin may decrease the degree of airway responsiveness in pa-
tients with bronchiectasis and increased airway responsiveness
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The study was conducted in a dou-
ble-blind, randomized, placebo-controlled
fashion after the preliminary methacholine
challenge test”
Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk “A doctor (not responsible for follow-up
or data analysis) was assigned the task of
dividing the patients into two groups”
Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The study was conducted in a dou-
ble-blind, randomized, placebo-controlled
fashion after the preliminary methacholine
challenge test”
Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two participants (1 in each group) were
withdrawn from the study because of
non-compliance with medication or regu-
lar check-up. Missing outcome data were
balanced in numbers across intervention
groups, and reasons for missing data were
similar across groups
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Other bias Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Liu 2012
Methods Aims: to assess the effect of roxithromycin on inflammation media in induced sputum,
dilated bronchial wall thickness, SGRQ scores, and exacerbation rates
Design: open-label, randomised controlled trial
Total study duration: 6 months
Number of study centres and location: 1, Qinzhou City, Guangxi Province, China
Study setting: hospital
Methods of recruitment: not reported
Withdrawals: 4, number per group not reported; reasons for withdrawal not reported
Study start/end dates: June 2007/June 2010
Analysis by intent-to-treat: no
Participants 50 adults were randomised.
Inclusion criteria: aged 18 to 65 years with bronchiectasis diagnosed by HRCT
Exclusion criteria: allergy to macrolide, cirrhosis, liver dysfunction and exacerbation.
Bronchiectasis exacerbation was defined as abnormalities in 4 of the following 9 symp-
toms, signs, or laboratory findings: change in sputum production (consistency, colour,
volume, or hemoptysis); increased dyspnoea (chest congestion or shortness of breath);
increased cough; fever (38° C); increased wheezing; decreased exercise tolerance, malaise,
fatigue, or lethargy; FEV1 or FVC decreased 10% from a previously recorded value;
radiographic changes indicative of a new pulmonary process; or changes in chest sounds.
Concomitant medications unclear
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Mean age: intervention group: 47, SD 8; control group: 49, SD 9 (range 29-67)
Gender: intervention group: 12 male, 13 female; control group: 14 male, 11 female
Bronchiectasis criteria: HRCT
Severity of condition: not reported
Baseline lung function (intervention group, control group): not reported
Smoking history: intervention group, control group, pack-years: not reported
Baseline imbalances: not reported
Interventions Intervention group: roxithromycin + ambroxol hydrochloride (n = 25)
Dose (Rox): 15 g (150 mg); delivery mode: oral; frequency: 1/d; duration: 6 months+
Dose (AH): 30 mg; delivery mode: oral; frequency: 3/d; duration: 6 months
Control group: oral ambroxol hydrochloride (n = 25)
Dose: 30 mg; delivery mode: oral; frequency: 3/d; duration: 6 months
Adherence: not reported
Run-in phase: not reported
Run-out phase: not reported
Outcomes Primary: unclear
Secondary: SGRQ and MRC Breathlessness Scale
Time points: baseline, 6 months
Post hoc analysis: unclear
Notes Power calculation: not reported
Trial registration: not reported
Conflicts of interest: unclear
Funders: Chinese Medical Association Chronic Pulmonary Disease
Fund (07010150023), Guangxi ProvinceDepartment of Science Youth Fund (0991019)
, Guangxi Province Health Department Self-funded Research Project (Z2007047)
Role of the sponsors: unclear
Ethical approval: unclear
Conclusions: Scores for bronchial wall thickening of bronchiectasis were increased in
participants with stable bronchiectasis. Low-dose roxithromycin combined with am-
broxol hydrochloride significantly improved degree of dyspnoea and reduced scores for
extent of bronchiectasis, scores for bronchial wall thickening of bronchiectasis, and global
CT scores as compared with treatment with ambroxol hydrochloride alone in partici-
pants with bronchiectasis who were in stable condition
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random number table”
Allocation concealment (selection bias) Unclear risk Information in study report was insuffi-
cient.
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Reporting was unclear, but this was an
open-label study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded to group
allocation.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4 withdrawals were reported, but numbers
for each group were not given
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Other bias Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Liu 2014
Methods Aims: to assess effects of roxithromycin on inflammation media in induced sputum,
dilated bronchial wall thickness, SGRQ scores, and exacerbation of bronchiectasis in
patients in stable condition
Design: open-label, randomised controlled trial
Total study duration: 26 months
Number of study centres and location: 1, China
Study setting: Tenth Affiliated Hospital of Guangxi Medical University
Methods of recruitment: unclear
Withdrawals: intervention group: 4; control group: 5
Study start/end dates: May 2009/July 2011
Analysis by intent-to-treat: no
Participants 52 adults randomised; 43 completed
Inclusion criteria: between 18 and 65 years of age and hospitalised at the Tenth Affiliated
Hospital of Guangxi Medical University directed by First Affiliated Hospital of Guangxi
Medical University, Qinzhou, China, from May 2009 to July 2011
Exclusion criteria: protocol-defined exacerbation (PDE) of bronchiectasis. PDE was
prospectively defined as abnormalities in 4 of the following 9 symptoms, signs, or labora-
tory findings: change in sputum production (consistency, colour, volume, or haemopty-
sis); increased dyspnoea (chest congestion or shortness of breath); increased cough; fever
(> 38° C); increased wheezing; decreased exercise tolerance, malaise, fatigue, or lethargy;
FEV1 or FVC decreasing 10% from a previously recorded value; radiographic changes
indicative of a new pulmonary process; or changes in chest sounds. Patients with CF
who had documented clinical, radiological, and genotypic features and abnormal sweat
test results (sweat sodium and chloride > 60 mmol/L) were excluded. Patients who were
allergic to macrolides and patients with impaired hepatic disease or diabetes mellitus
were also excluded
Mean age: intervention group: 47.1 years; control group: 49.2 years
Gender: intervention group: 11 women, 11 men; control group: 9 women, 12 men
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Bronchiectasis diagnosis: standard chest radiograph compatible with bronchiectasis,
for instance, fusiform infiltrates of mucoid impaction, “signet ring”, or “tram tracks”;
chest CT showing ectasia of peripheral bronchi, fluid-filled airways, or thickening of the
mucosa; daily chronic sputum production or haemoptysis - all confirmed at baseline by
HRCT
Severity of condition: global CT score: intervention group: 9.47; control group: 9.54
Baseline lung function (intervention group, control group): FEV1 (L) 1.59, 1.63;
FEV1 (% predicted): 66.8, 67.4; FVC (L) 2.27, 2.34; FVC (% predicted): not reported;
FEV1/FVC: 70, 69.6
Smoking history: intervention group: 4.7 pack-years; control group: 4.3 pack-years
Baseline imbalances: no significant differences between study groups at baseline
Interventions Intervention group: roxithromycin (n = 22)
Dose: 150 mg; delivery mode: oral; frequency: 1/d; duration: 6 months
Control group: no treatment (n = 21)
Adherence: Treatment adherence was encouraged by telephone calls from the study co-
ordinator and by measurement of pill counts
Run-in phase: 1-month run-in period free of exacerbation symptoms before baseline
sampling
Run-out phase: not reported
Outcomes Primary: not specified
Secondary: sputum production, lung function, inflammatory markers (including IL-8,
neutrophil elastase (NE), MMP-9, tissue inhibitor of metalloproteinases-1 (TIMP-1),
hyaluronidase (HA), and type IV collagen concentration in induced sputum), total and
differential sputum cell counts, quality of life (SGRQ), dyspnoea, CT evaluation of the
thorax
Time points: baseline, 6 months
Post hoc analysis: NA
Notes Power calculation: not reported
Trial registration: not reported
Conflicts of interest: none
Funders: Trial authors acknowledge support from the Medical Experiment Center
of Guangxi Medical University. The study was supported by grants from the Spe-
cial Foundation for Chronic Respiratory Disease of Chinese Medical Association (no.
07010150023) and Youth Science Fund of Guangxi Zhuang Autonomous Region in
China (no. 0991019)
Role of the sponsors: not reported
Ethical approval: yes
Conclusions: Treatment with roxithromycin can decrease airway inflammation and
reduce airway thickness of dilated bronchus, both of which are positively associated with
chronic airway inflammation in steady-state bronchiectasis
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Eligible participants were randomly as-
signed to control and roxithromycin
groups; information is insufficient to per-
mit judgement of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Low risk Study report information was insufficient.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Reporting was unclear but this was an
open-label study.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal was balanced between groups.
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Other bias Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Lourdesamy 2014
Methods Aims: to demonstrate effects of azithromycin on sputum volume, quality of life, and
independence, and to estimate duration of effects of azithromycin after cessation of
therapy
Design: double-blind, randomised, placebo-controlled trial
Total study duration: 26 weeks
Number of study centres and location: single, Malaysia
Study setting: Respiratory Clinic, Hospital Taiping, Taiping; unclear whether in-patient
or out-patient setting
Methods of recruitment: not reported
Withdrawals: 10 adults lost to follow-up (intervention group: 6; control group: 4)
Study start/end dates: November 2011/December 2013
Analysis by intent-to-treat: no
Participants 78 adults were randomised.
Inclusion criteria: over 18 years of age with diagnosis of bronchiectasis, reproducible
spirometry and chronic sputum production documented in second week of the run-in
period; stable for 6 weeks before study entry
Exclusion criteria: pregnant and lactating, active tuberculosis, malignancy
Mean age: intervention group: 65.94 years; control group: 59.74 years
Gender: intervention group: 24 women, 15 men; control group: 26 women, 13 men
Bronchiectasis diagnosis: HRCT
Severity of condition: not reported
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Baseline lung function (intervention group, control group): FEV1 (L): 1.09, 1.17;
FVC (L): 1.56, 1.69; FEV1/FVC: 72.6, 70.90
Smoking history: intervention group: 11 current smokers, 28 non-smokers; control
group: 11 current smokers, 28 non-smokers
Baseline imbalances: no significant differences between treatment groups at baseline
with respect to age, gender, weight, height, smoking status, serum albumin and creatinine
levels, SGRQ scores, and lung function. Baseline sputum volume was significantly higher
in the azithromycin group
Interventions Intervention group: azithromycin (n = 39)
Dose: 1000 mg; delivery mode: oral; frequency: weekly; duration: 12 weeks
Control group: placebo (n = 39)
Identical to Zithromax tablets
Adherence: not reported
Run-in phase: 2 weeks
Run-out phase: 12 weeks; both groups received placebo
Outcomes Primary: 24-hour sputum volume (percentage change from baseline)
Secondary: SGRQ score, SGRQ (change in score from baseline) and spirometric assess-
ment of FVC and FEV1, adverse events, serious adverse events
Post hoc analysis: unclear
Notes Power calculation: “The study was powered to detect differences in sputum volume,
quality of life and spirometry values with azithromycin treatment”
Trial registration: clinicaltrials.gov: NCT02107274
Conflicts of interest: See role of sponsors below; conflicts of interest for individual trial
authors not stated
Funders: grant approved by theMinistry of Health of Malaysia. Study medications were
manufactured and provided by Pfizer Inc. (Ann Arbor, Ml, USA)
Role of the sponsors: Pfizer Ltd. (Sandwich, Kent, UK) was not involved in study
design, data collection, or data interpretation
Ethical approval: yes (local institutional ethics committee)
Conclusions: 12-Week administration of 1000 mg azithromycin weekly in pulmonary
bronchiectasis significantly reduced mean sputum volume, improved health status, and
stabilised lung function. Azithromycin had a ’carryover effect’ on sputum volume and
health status for 12 weeks after cessation of therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number se-
quence in a 1:1 ratio
Allocation concealment (selection bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients were randomised to receive 12
weeks of placebo or azithromycin in a 1:1
ratio in a double-blinded fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was maintained from randomisa-
tion until database lock unless any patient
emergencies arose
Incomplete outcome data (attrition bias)
All outcomes
Low risk Tenparticipants did not complete the study
and were excluded from analyses. Four par-
ticipants were lost to follow-up for lo-
gistic reasons. Another 4 had gastroin-
testinal (GI) disturbances, which consisted
predominantly of diarrhoea. Two deaths
were recorded in the treatment arm. Both
participants passed away owing to severe
pneumonia. Missing outcome data were
balanced in numbers across intervention
groups, and reasons for missing data were
similar across groups
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes of interest in the review
have been reported in the prespecified way
Other bias High risk Groups were not balanced at baseline with
regard to the primary outcome - sputum
volume
Masekela 2013
Methods Aims: to evaluate the efficacy of erythromycin compared with placebo in reducing the
number of pulmonary exacerbations among children with HIV-related bronchiectasis
over a period of 52 weeks
Design: randomised, double-blind, placebo-controlled trial
Total study duration: not reported
Number of study centres and location: single, South Africa
Study setting: Paediatric Chest Clinic, Steve Biko Academic Hospital, Pretoria
Methods of recruitment: not reported
Withdrawals: 1 child died after randomisation, but group allocation was not stated, and
10 were lost to follow-up (intervention group: 6; control group: 4)
Study start/end dates: January 2009/June 2012
Analysis by intent-to-treat: no
Participants 42 children were randomised.
Inclusion criteria: children aged 6 to 18 years with confirmed HIV infection. The
presence of bronchiectasis was confirmed on HRCT scanning, with exclusion of other
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causes of bronchiectasis, including a sweat test to rule out CF. All children had to be able
to perform reliable pulmonary function tests
Exclusion criteria: abnormal liver function tests (ALT/AST > 2.5 times normal); ab-
normal urea/creatinine; use of carbamazepine, warfarin, cyclosporine, or long-term mi-
dazolam
Mean age: intervention group: 8.4 years; control group: 9.1 years
Gender: intervention group: 4 girls, 13 boys; control group: 9 girls, 5 boys
Bronchiectasis diagnosis: HRCT scanning
Severity of condition: Bhalla score: intervention group: 15; control group: 11.5
Baseline lung function (intervention group, control group): FEV1 (% predicted):
56, 53.6; FVC (% predicted): 49, 45
Baseline imbalances: Characteristics of the 2 study arms were generally balanced, with
the exception of gender distribution, with more males (76%) in the erythromycin arm
and more females in the placebo arm (64%). CD4 count (%) and CD4 (total × 106)
were significantly lower and Bhalla score significantly higher in the intervention group
than in the control group (worse)
Interventions Intervention group: erythromycin (n = 17)
Dose: 125 mg per oral suspension if < 15 kg body weight, or 250 mg per oral suspension
if ≥ 15 kg body weight; delivery mode: oral; frequency: daily; duration: 52 weeks
Control group: placebo (n = 14)
Adherence: Compliance was assessed with use of a medication diary and verbal inter-
views. 90% of participants in each arm took their medication
Run-in phase: unclear
Run-out phase: unclear
Outcomes Primary: exacerbations (protocol defined as the presence of ≥ 2 of the following: in-
creased tachypnoea or dyspnoea, change in frequency of cough, increase in sputum pro-
ductivity, fever, chest pain, new infiltrates on chest x-ray)
Secondary: pulmonary function parameters (FEV1, FVC, FEF), BMI z-score, CD4
count (%), CD4 (total* 108), proinflammatory and anti-inflammatory chemokines and
cytokines, Bhalla score
Post hoc analysis: unclear
Notes Power calculation: Sample size calculation was based on the number of pulmonary
exacerbations requiring antibiotic therapy, estimated at 3 per year. A sample size of 20
participants per study arm was determined to have 90% power to detect a clinically
relevant reduction in exacerbations of 30%, when a mean of 2 and a standard deviation
of 1 exacerbation were assumed; and with a presumed dropout rate of 10% when testing
was 1sided at the 0.05 level of significance
Trial registration: not reported
Conflicts of interest: not declared
Funders: unrestricted grant from the Research Development Program of the University
of Pretoria. Adcock Ingram South Africa donated erythromycin
Role of the funders/sponsors: not reported
Ethical approval: yes
Conclusions: Administration of HAART and adjunctive care, which includes airway
clearance and treatment of exacerbations, in children with HIV-related bronchiectasis is
associated with significant improvement in pulmonary function tests and IL-8, with no
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additional benefit derived from the use of erythromycin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned (1:1)
to the erythromycin group (55%) or to the
placebo group (45%)
Allocation concealment (selection bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk All study personnel performing clinical
evaluations were blinded to treatment as-
signment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Two blinded radiologists carried out the
CT scan. Additional details on outcome
blinding were not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10 participants were lost to follow-up - 4 in
the placebo group and 6 in the intervention
group; no reasons were provided
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Other bias Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Sadigov 2013
Methods Aims: to test the hypothesis that azithromycin would decrease the frequency of exacer-
bations, increase lung function, and decrease the severity of symptoms
Design: randomised placebo-controlled trial
Total study duration: 12 months
Number of study centres and location: single, Azerbaijan
Study setting: hospital clinic
Methods of recruitment: not reported
Withdrawals: unclear
Study start/end dates: February 2011/February 2012
Analysis by intent-to-treat: unclear
Participants 65 adults were randomised.
Inclusion criteria: not reported
Exclusion criteria: not reported
Mean age: not reported
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Gender: not reported
Bronchiectasis diagnosis: not reported
Severity of condition: not reported
Baseline lung function: not reported
Smoking history: not reported
Baseline imbalances: not reported
Interventions Intervention group: azithromycin (n = 35)
Dose: 500 mg; delivery mode: oral; frequency: 3 days per week; duration: 6 months
Control group: placebo (n = 30)
Adherence: unclear
Run-in phase: unclear
Run-out phase: unclear
Outcomes Primary: event-based exacerbations, times of first exacerbation, adverse events, serious
adverse events
Secondary: sputum volume and purulence, FEV1, systemic and local markers of infec-
tion (leucocyte count, CRP, neutrophil count of induced sputum, interleukin-6 (IL-6)
in induced sputum), adverse events (e.g. cardiac arrhythmias, gastrointestinal symptoms,
hearing impairment)
Notes Conference abstract only. Additional information provided by personal communication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Allocation concealment (selection bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
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Other bias Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’ as
only data from the conference abstract were
available
Serisier 2013
Methods Aims: to test the hypothesis that low-dose erythromycin would reduce pulmonary exac-
erbations in patients with non-CF bronchiectasis with a history of frequent exacerbations
Design: randomised, double-blind, placebo-controlled study
Total study duration: 26 months
Number of study centres and location: single, Australia
Study setting: regional adult CF centre, respiratory medicine department, Australian
University Teaching Hospital; out-patient setting
Methods of recruitment: patients attending the centre, referral from respiratory physi-
cians at other centres, and public radio advertisements
Withdrawals: 10; intervention group: 5 (2 lost to follow-up, 1 lost for possible QTc
prolongation, 1 moved, 1 unable to continue); control group: 5 (2 lost to follow-up, 1
with nausea, 1 withdrawn by physician, 1 unable to continue)
Study start/end dates: October 2008/December 2011
Analysis by intent-to-treat: yes, using LOCF for missing data
Participants 117 adults were randomised.
Inclusion criteria: confirmed diagnosis of bronchiectasis and clinically stable for at least
4 weeks before enrolment (defined as no symptoms of exacerbation, no requirement for
supplemental antibiotic therapy, and FEV1 within 10% of best recently recorded value
when available)
Exclusion criteria:CF, currentmycobacterial disease or bronchopulmonary aspergillosis,
any reversible cause for exacerbations, maintenance oral antibiotic prophylaxis, prior
macrolide use except short-term use, changes to medications in the preceding 4 weeks,
cigarette smoking within 6 months, medications or comorbidities with the potential for
important interactions with erythromycin
Mean age: intervention group: 61.1 years; control group: 63.5 years
Gender: intervention group: 38 women, 21 men; control group: 33 women, 25 men
Bronchiectasis diagnosis: HRCT scan and clinical diagnosis (≥ 2 separate pulmonary
exacerbations requiring supplemental systemic antibiotic therapy in the preceding 12
months, and daily sputum production)
Severity of condition: 35% of adults had more than 5 exacerbations in the previous
year. Bhalla score was not reported
Baseline lung function (intervention group, control group): FEV1 (postbronch %
predicted): 70.2, 73.6
Smoking history: intervention group: ex-smokers: 10, 2.3 pack-years: non-smokers: 49;
control group: ex-smokers: 15, 2.9 pack-years: non-smokers: 44
Baseline imbalances: no significant between-group differences
Interventions Intervention group: erythromycin ethylsuccinate (n = 59)
Dose: 400mg (equivalent to 250mg erythromycin base); deliverymode: oral; frequency:
2/d; duration: 48 weeks
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Control group: placebo (n = 58) spray-dried lactose/magnesium stearate tablets
Adherence: assessed at each visit by pill counts (intervention group: 95.6%; control
group: 96.5%)
Run-in phase: unclear
Run-out phase: 4-week washout period
Erythromycin and placebo tablets were manufactured and supplied by Alpha Pharm and
were identical in shape, appearance, and taste
Outcomes Primary:mean rate of protocol-defined pulmonary exacerbation (PDPE) per patient per
year (required antibiotic administration for a sustained (> 24-hour) increase in sputum
volume or purulence accompanied by new deteriorations in ≥ 2 additional symptoms:
sputum volume, sputum purulence, cough, dyspnoea, chest pain, or hemoptysis
Secondary: rate of all pulmonary events (i.e. PDPEs plus non-PDPEs) for which par-
ticipants commenced antibiotics, total days of antibiotics, change in the proportion of
commensal oropharyngeal streptococci resistant to macrolides, symptoms (LCQ), qual-
ity of life (SGRQ), 24-hour sputum weight, FEV1 percent predicted, CRP level, exercise
capacity (6MWT), sputum bacteriology, and sputum inflammatory cell counts. Safety
endpoints included adverse events, liver function test results, and electrocardiogram find-
ings
Post hoc analysis: unclear
Notes Power calculation: Assuming a baseline (SD) annual rate of exacerbations in the control
group of 2.9 (1.2), 98 participants gave 90% power at the 5% significance level to show
a 28% reduction in exacerbation rate with erythromycin - a much more conservative
estimate of efficacy than the 50%reduction seen in our uncontrolled pilot data. Assuming
20% attrition, the required sample size was increased to 118
Trial registration: anzctr.org.au Identifier: ACTRN12609000578202
Conflicts of interest: Dr. Serisier received honoraria, speakers’ fees, and travel support
from a range of pharmaceutical companies including GSK, Boehringer-Ingelheim, As-
traZeneca, Phebra, and Pharmaxis. Dr. Bowler received honoraria, speakers’ fees, and
travel support from a range of pharmaceutical companies including GSK, Boehringer-
Ingelheim, AstraZeneca, and Novartis. Other trial authors reported no conflicts of in-
terest
Funders: Mater Adult Respiratory Research Trust Fund. No pharmaceutical company
or other agency (including medical writers) had any role in this study
Role of the sponsors: The funding source had no role in design and conduct of the
study; collection, analysis, and interpretation of data; or preparation, review, or approval
of the manuscript
Ethical approval: yes
Conclusions: Among patients with non-CF bronchiectasis, 12- month use of ery-
thromycin compared with placebo resulted in a modest decrease in the rate of pulmonary
exacerbations and an increased rate of macrolide resistance
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quences, blocked in random groups of 2, 4,
and 8 and stratified for the presence of spu-
tum Pseudomonas aeruginosa at screening,
were held by the Department of Pharmacy.
Allocation concealment (selection bias) Low risk The independent trial pharmacist dis-
pensed blinded study drug according to the
randomisation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial participants, trial supervisors, and all
trial staff directly involved in participant
care were unaware of treatment assignment
at all times
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants and study personnel were
masked to treatment assignment, including
all investigators involved in sample process-
ing and data entry
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss of follow-up was similar in both
groups.
Selective reporting (reporting bias) Low risk All measurements stated in the methods
were reported in the results section. Ex-
tended methods were available online (
http://www.jama.com).
Other bias Low risk Trial authors used LOCF methods to im-
pute missing data for ITT analyses, but ro-
bustness was confirmed via multiple impu-
tation techniques to assess sensitivity
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Methods Aims: to establish whether long-term (12 to 24 months) antibiotic treatment with
azithromycin would reduce the rate of pulmonary exacerbations in indigenous children
with non-cystic fibrosis bronchiectasis; also to monitor for serious adverse events asso-
ciated with azithromycin and examine its effect on nasopharyngeal carriage of bacterial
pathogens
Design: double-blind, randomised, placebo-controlled trial
Total study duration: 25 months
Number of study centres and location: multi-centre, Australia and New Zealand
Study setting: community clinics in central and northern Australia and urban Maori
and Pacific Island children from a tertiary paediatric hospital in Auckland
Methods of recruitment: Children entered the study when they were clinically stable
(≥ 8 weeks after their last exacerbation) as decided by clinic staff
Withdrawals: intervention group: 4 (1 was withdrawn by physician, 1 was withdrawn
by parent, 1 refused meds, 1 fulfilled exit criteria); control group: 4 (2 withdrawn by
physician, 1 moved out of study, 1 fulfilled exit criteria)
Study start/end dates: November 2008/December 2010
Analysis by intent-to-treat: Analysis of the primary endpoint was by intention-to-
treat. Analysis of secondary endpoints was by modified intention-to-treat, excluding
participants with missing data, except for analysis of nasal swabs, which was done only
for participants with swabs available from baseline and last clinic visits
Participants 89 children were randomised.
Inclusion criteria: aged 1 to 8 years, living within the study area, had bronchiectasis con-
firmed radiographically by HRCT scans or chronic suppurative lung disease (bronchiec-
tasis suspected clinically when HRCT scans were unavailable), and had ≥ 1 pulmonary
exacerbation in the past 12 months
Exclusion criteria: receiving chemotherapy, immunosuppressive treatment, or long-
term antibiotics; had an underlying cause for their bronchiectasis (e.g. cystic fibrosis,
primary immunodeficiency), other chronic disorders (e.g. cardiac, neurological, renal,
or hepatic abnormality), or macrolide hypersensitivity
Mean age: intervention group: 3.99 years; control group: 4.22 years
Gender: intervention group: 19 girls, 26 boys; control group: 23 girls, 21 boys
Bronchiectasis diagnosis:HRCT scans or chronic suppurative lung disease (bronchiec-
tasis suspected clinically when HRCT scans were unavailable)
Severity of condition: Bhalla score not reported
Baseline lung function: not reported
Baseline imbalances: The most substantial difference was mechanical ventilation, with
more children in the placebo group needing ventilation as neonates compared with those
in the azithromycin group (22% vs 5%). However, participants in the azithromycin
group were less likely to be premature (29% vs 39%), fewer had proven bronchiectasis
(76% vs 89%), and their first admission to hospital for respiratory disease occurred later
in life (mean of 6.5 vs 4.2 months)
Interventions Intervention group: azithromycin (n = 45)
Dose: 30 mg/kg, maximum 600 mg; delivery mode: oral; frequency: once a week;
duration: 24 months
Study drugwas administered under direct supervision at the community clinic (Australia)
or at the child’s home, preschool, or school (New Zealand)
Control group: placebo (n = 44)
Placebo medication was similar in appearance, taste, smell, and packaging to the active
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medication and had no active ingredients
Adherence: Research nurses contacted the community clinic and the child’s caregiver,
preschool, or school weekly to record drug adherence (children receiving medication
and, if any, children who were absent from the community) and any issues with admin-
istration, such as the child spitting out the medication. These data were recorded in a
participant medication logbook. Study personnel completed a medical review every 3 to
4 months. Intervention group: 88%; control group: 84%
Run-in phase: Children who were already receiving azithromycin (4 in each treatment
group) had the antibiotic discontinued and underwent a 3-month washout period before
commencing the study
Run-out phase: unclear
Both azithromycin and placebo were provided in powder format and were reconstituted
with 9 mL of sterile water to syrup for oral use (40 mg/mL)
Outcomes Primary: pulmonary exacerbation rate (treatment by clinic or hospital staff with an-
tibiotics for any of the following (as recorded in the medical chart): increased cough,
dyspnoea, increased sputum volume or colour intensity, new chest examination or radio-
graphic findings, deterioration in predicted FEV1 percentage > 10%, or haemoptysis)
Secondary: time to first pulmonary exacerbation, duration of exacerbation episode (dis-
charge date minus admission date plus 1 day), severity (admission to hospital, oxygen
supplementation), weight-for-age z-scores (z-score at last study clinic minus its value at
baseline), respiratory signs and symptoms (assessed by study personnel on history and
physical examination), sputum characteristics, school absenteeism, FEV1 %predicted in
those aged 6 years and older, serious adverse events, and antibiotic resistance in bacterial
pathogens cultured from deep nasal swabs
Post hoc analysis: post hoc subgroup analyses for participants taking ≥ 70% of their
expected doses, those who received the intervention for 23 to 24 months, children
with HRCT-proven bronchiectasis, children with ≥ 2 hospital-managed pulmonary
exacerbations before enrolment, children with ≥ 10 pulmonary exacerbations before
enrolment, those without a history of mechanical ventilation, and those carrying any
respiratory bacterial pathogens at baseline
Notes Power calculation: Sample size and power calculations were based on previous data; we
anticipated that participants in the placebo group would have 4 episodes during the 24-
month trial period. Guided by results from an earlier randomised trial of azithromycin
in patients with CF, we assumed pulmonary exacerbations would be reduced by 50%
in the intervention group and by 15% in the placebo group. 51 participants per group
would give 90% power to detect an average difference of 1.4 respiratory exacerbations
per participant over a 2-year period at the 5% level of significance
Trial registration: Australian New Zealand Clinical Trials Registry, number AC-
TRN12610000383066
Conflicts of interest: Trial authors declared they had no conflicts of interest.
Funders: National Health and Medical Research Council (NHMRC) of Australia
(project grant numbers 389837 (clinical component), 545223 (microbiology compo-
nent), and CRE for lung health 1040830 (feedback)); Telstra Foundation (seeding grant
- Telstra Community Development Grant, 2004); Health Research Council of New
Zealand (grant number 08/158); and Auckland Medical Research Foundation (grant
number 81542)
Role of the sponsors: Sponsors of the study had no role in study design, data collection,
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data analysis, or data interpretation, nor in writing of the report
Ethical approval: yes
Conclusions:Once-weekly azithromycin for up to 24 months decreased pulmonary ex-
acerbations among indigenous children with non-cystic fibrosis bronchiectasis or chronic
suppurative lung disease. However, this strategy was accompanied by increased carriage
of azithromycin-resistant bacteria, the clinical consequences of which are uncertain, and
will need careful monitoring and further study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent statistician used a com-
puter-generated permuted-block design
to provide the randomisation sequences.
Childrenwere allocated in a 1:1 ratio (strat-
ified by study site and exacerbation fre-
quency in the preceding 12 months (1-2 vs
> 3 episodes)) to azithromycin or placebo
Allocation concealment (selection bias) Low risk Allocation concealment was achieved by
use of sequentially numbered, double-
sealed, opaque envelopes. An independent
person at theQueensland Institute ofMed-
ical Research (Brisbane, QLD, Australia)
prepared the individual envelopes labelled
with a randomisation number that con-
tained the treatment code inside
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs (powder for reconstitution
to suspension) were provided in identical
packaging, and the placebo (Institute of
Drug Technology, Melbourne, VIC, Aus-
tralia) was much the same in appearance,
taste, and smell to azithromycin (Pfizer
Australia, West Ryde, NSW, Australia).
Participants, families, health professionals,
and study personnel were unaware of treat-
ment assignment until data analysis was
completed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators collecting data were unaware
of the treatment assigned to each child
Incomplete outcome data (attrition bias)
All outcomes
Low risk Eight children (4 per group) ceased the
intervention early, mainly after they were
withdrawn by their treating physician or
because they experienced treatment fail-
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ure (2 in the azithromycin group, 3 in the
placebo group)
Selective reporting (reporting bias) Low risk The study protocol is available, and all of
the study’s prespecified (primary and sec-
ondary) outcomes of interest to the review
were reported in the prespecified way
Other bias Low risk Baseline imbalances were tested in post hoc
subgroup analyses and showed increased ef-
ficacy for the intervention group, although
as the trial authors note, analyses were not
hypothesis driven and results should there-
fore be interpreted with caution
Wong 2012
Methods Aims: to test whether azithromycin decreases the frequency of exacerbations, increases
lung function, and improves HRQoL in patients with non-CF bronchiectasis
Design: randomised, double-blind, placebo-controlled trial
Total study duration: 18 months
Number of study centres and location: 3, New Zealand
Study setting: health centres
Methods of recruitment: not reported
Withdrawals: 4withdrew from the azithromycin group (1 had adverse events, 2were lost
to follow-up, 1 withdrew consent); 10 withdrew from the placebo group (2 had adverse
events, 3 were lost to follow-up, 4 withdrew consent, 1 had cultured Mycobacterium
avium intracellulare in sputum).
Study start/end dates: February 2008/October 2009
Analysis by intent-to-treat: yes
Participants 141 adults were randomised.
Inclusion criteria: ≥ 18 years of age, ≥ 1 pulmonary exacerbation requiring antibiotic
treatment in the past year, and diagnosis of bronchiectasis defined by HRCT scan
Exclusion criteria: history of CF; hypo-gammaglobulinaemia; allergic bronchopul-
monary aspergillosis; positive culture of non-tuberculous mycobacteria in the past 2 years
or at screening; macrolide treatment for more than 3 months in the past 6 months; or
unstable arrhythmia
Mean age: intervention group: 60.9 years; control group: 59 years
Gender: intervention group: 48 women, 23 men; control group: 50 women, 20 men
Bronchiectasis diagnosis: HRCT scan
Severity of condition: Bhalla score not reported
Baseline lung function (intervention group, control group): FEV1 (% predicted):
67.1, 67.3; FVC (% predicted): 77.7, 78.5; FEV1/FVC: 65.4%, 64.7%
Smoking history: not reported
Baseline imbalances: unclear
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Interventions Intervention group: azithromycin (n = 71)
Dose: 500mg; deliverymode: oral; frequency: 3/week (Monday,Wednesday, and Friday)
; duration: 6 months
Control group: placebo (n = 70)
Adherence: intervention group: 97.9%; control group: 98.3%, assessed by pill counts
Run-in phase: not reported
Run-out phase: followed up for another 6 months without treatment
Outcomes Primary: rate of event-based exacerbations in the first 6 months (increase in or new
onset of ≥ 1 pulmonary symptom (sputum volume, sputum purulence, or dyspnoea)
requiring treatment with antibiotics), FEV1 before bronchodilation, and SGRQ total
score at the end of the treatment period
Secondary: time to first exacerbation, rate of symptom-based exacerbations (increase in
or new onset of ≥ 1 pulmonary symptom reported on the daily diary card and mean
of 3 symptom scores from the daily diary card on 2 consecutive days had to increase
by ≥ 1 point (on a 5-point scale) compared with the same calculation 1 week earlier)
, prebronchodilator and postbronchodilator FVC, postbronchodilator FEV1, exercise
capacity (as measured by the 6MWT), SGRQ total score at 12 months, concentration
of CRP (assessed only at 6 months), sputum cell counts and microbiology, and adverse
events
Post hoc analysis: unclear
Notes Power calculation:We estimated that about 134 patients would need to be enrolled for
the study to have 80% power to detect a 33% difference between the 2 groups in the
Poisson frequency of exacerbations during the 6-month treatment period, assuming a
2-sided level of 0 to 5 and a 10% dropout rate. With the assumption of normality, the
study had power of 89% to detect a difference of 0 to 16 L in the prebronchodilator
FEV1 and power of 87% to detect a difference of 8 units in SGRQ total score
Trial registration: Australian New Zealand Clinical Trials Registry, number AC-
TRN12607000641493
Conflicts of interest: Trial authors declared they had no conflicts of interest.
Funders:Health Research Council of NewZealand and AucklandDistrict Health Board
Charitable Trust
Role of the sponsors: The sponsor had no role in study design, data collection, data
analysis, or data interpretation. The data monitoring committee of the sponsor provided
feedback on the completed report. The corresponding author had full access to all data
in the study and had final responsibility for the decision to submit for publication
Ethical approval: yes
Conclusions:Azithromycin, taken 3 times a week for 6months, decreased the frequency
of event-based exacerbations and increased the time to first exacerbation in patients with
non-cystic fibrosis bronchiectasis. A treatment effect on exacerbations was evident 6
months after completion of treatment
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer- generated random number list.
Patients were randomly assigned in a 1:1
ratio with a permuted block size of 6 and
sequential assignment, stratified by centre
Allocation concealment (selection bias) Low risk Randomly assigned to receive azithromycin
or placebo by a statistician independent of
the reporting statistician
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, research assistants, and inves-
tigators were masked to treatment alloca-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, research assistants, and inves-
tigators were masked to treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 withdrew from the intervention group
and 10 from the placebo group for similar
reasons
Selective reporting (reporting bias) Low risk All outcomes specified in the protocol were
reported.
Other bias Low risk None identified
Yalcin 2006
Methods Aims: to evaluate effects of macrolide antibiotics on the process of inflammation (by
measuring IL-8, TNF-a, IL-10 levels and cell profiles in BAL fluid), pulmonary function,
and sputum production in children with steady-state bronchiectasis, secondary to causes
other than CF or primary immunodeficiencies
Design: randomised controlled trial (open-label, as no placebo)
Total study duration: 12 months
Number of study centres and location: single, Turkey
Study setting:Department of Paediatric Chest Diseases at Hecettepe University Faculty
of Medicine
Methods of recruitment: unclear
Withdrawals: none
Study start/end dates: April 1999/March 2000
Analysis by intent-to-treat: yes
Participants 34 children were randomised.
Inclusion criteria: diagnosis of bronchiectasis not due to CF or primary immunodefi-
ciencies, clinically stable with no evidence of acute pulmonary exacerbations; no history
of upper or lower respiratory tract infection for at least 4 weeks before start of the study.
No patients had received antibiotics within 4 months of study entry. None had taken
oral or inhaled corticosteroids before or during the study
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Exclusion criteria: not reported
Mean age: intervention group: 13.1 years; control group: 11.9 years
Gender: intervention group: 9 girls, 8 boys; control group: 6 girls, 11 boys
Bronchiectasis diagnosis: clinical and high-resolution computed tomography
Severity of condition: not reported
Baseline lung function (intervention group, control group): FEV1 (% predicted):
74, 79
Baseline imbalances: Data show no statistically significant differences between study
and control groups in age, sex, FEV1, or oxygen saturation. But among inflammatory
parameters, IL-8 andTNF-a levels in BALfluidwere significantly higher at the beginning
of the study in the treatment group than in the control group (P = 0.02 and P = 0.02,
respectively)
Interventions Intervention group: clarithromycin (CAM) + supportive therapies (n = 17)
Dose: 15 mg/kg; delivery mode: oral; frequency: daily; duration: 3 months plus sup-
portive therapies (mucolytic and expectorant medications and postural drainage)
Control group: supportive therapies alone (mucolytic and expectorant medications and
postural drainage) (NB: no placebo) (n = 17)
Adherence: not reported
Run-in phase: unclear
Run-out phase: unclear
Outcomes Primary: unclear
Secondary: unclear
BAL cytokine levels (IL-8, IL-10, TNF-alpha); BAL cell profiles (cell number, neu-
trophils, macrophages); culture test (aerobic and anaerobic bacteria, fungi, andmycobac-
teria); pulmonary function test (FEV1, FEF); oxygen saturation; sputum volume
Post hoc analysis: unclear
Notes Power calculation: not reported
Trial registration: not reported
Conflicts of interest: not reported
Funders: SANOVEL Pharmaceuticals Inc., supplied cytokine kits.
Role of the sponsors: not reported
Ethical approval: not reported
Conclusions:Use of CAM in children with steady-state bronchiectasis results in labora-
tory improvement by reducing inflammatory processes in the lungs. No corresponding
clinical improvement could be shown, and although this is possible with long-term use,
trial validation is necessary
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information about the sequence generation
process was insufficient to permit judge-
ment of ’low risk’ or ’high risk’
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Allocation concealment (selection bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded as trial was not placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Treatment protocols for all participants
were completed without interruption, as
none experienced acute infection during
follow-up
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit
judgement of ’low risk’ or ’high risk’
Other bias High risk Inflammatory markers were significantly
higher in the intervention group at base-
line; it is unclear whether this was con-
trolled for in the change analysis
6MWT: six-minute walking test; AFB: acid-fast bacilli; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BAL: bron-
choalveolar lavage; BMI: body mass index; CD4: cluster of differentiation 4; CF: cystic fibrosis; COI: conflict of interest; CRP: serum
C-reactive protein; CT: computed tomography; EBC: exhaled breath condensate; FEF: forced expiratory flow; FeNO: fractional
exhaled nitric oxide; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HAART: highly active antiretroviral
therapy; HIV: human immunodeficiency virus; HRCT: high resolution computed tomography; HRQoL: health related quality of
life; ICS: inhaled corticosteroids; IL-6: interleukin-6; IL-8: Interleukin-8; IL-10: Interleukin-10; ITT: intention to treat; LABA:
long-acting beta-agonist; LCQ: Leicester Cough Questionnaire; LOCF: last observation carried forward; LRTI: lower respiratory
tract Infection; MMP-9: matrix metallopeptidase-9; MRC: Medical Research Council; NE: neutrophil elastase; NO2: nitrite; NO3:
nitrate; PC20: the Provocative Concentration of methacholine causing a 20% drop in FEV1; PDE: protocol-defined exacerbation;
PDPE: protocol-defined pulmonary exacerbation; PF: pulmonary function; PMN: polymorphonuclear leucocyte; QoL: quality of
life; QTc: theQT interval; SABA: short-acting beta-agonist; SD: standard deviation; SGRQ: St. George’s Respiratory Questionnaire;
TIMP-1: tissue inhibitor of metalloproteinases-1; TNF-alpha: tumour necrosis factor-alpha; WBC: white blood cell count.
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Chang 2013 Protocol
Kudo 1988 Not an RCT
Min 1988 Not an RCT; not exclusively bronchiectasis; duration of treatment < 4 weeks
Ming 2005 Not an RCT
Rikitomi 1988 Not an RCT
Saito 1988 Not an RCT
Tagaya 2002 Macrolide used for treatment as opposed to prevention; duration of treatment < 4 weeks
Unoura 1986 Not an RCT
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Tsang 1999
Methods Aims: to evaluate effects of low-dose erythromycin on sputum volume and lung function indices in steady-state
bronchiectasis
Design: double-blind placebo-controlled trial (trial authors contacted to determine whether randomised)
Total study duration: 6 months
Number of study centres and location: single, Hong Kong
Study setting: outpatient clinics at the University of Hong Kong
Methods of recruitment: not reported
Withdrawals: intervention group: 3 withdrawals - 2 were unreliable attenders, 1 developed a maculopapular rash 5
days after erythromycin therapy; control group: 0 withdrawals
Study start/end dates: October 1996/April 1997
Analysis by intent-to-treat: no
Participants 24 adults were randomised.
Inclusion criteria: 24-hour sputum volume > 10 mL; absence of unstable systemic disease; and “steady-state”
bronchiectasis (< 10% alteration of 24-hour sputum volume, forced expiratory volume in 1 second (FEV1), and
forced vital capacity (FVC); in the absence of deterioration in cough, dyspnoea, wheezing, fever, or chest pain at
baseline visits)
Exclusion criteria: unreliable clinic attendance, adverse reaction to macrolides, women who were lactating
Mean age: intervention group: 50 years; control group: 59 years
Gender: intervention group: 8 women, 3 men; control group; 8 women, 2 men
Bronchiectasis diagnosis: high-resolution computed tomography (HRCT)
Severity of condition: not reported
Baseline lung function: not reported
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Tsang 1999 (Continued)
Smoking history: intervention group: never: 10, ex-smoker: 1; control group: never: 8, ex-smoker: 2
Baseline imbalances: no significant differences between groups
Interventions Intervention group: erythromycin (n = 11)
Dose: 500 mg; delivery mode: oral; frequency: 2/d; duration: 8 weeks
Control group: placebo (n = 10)
Adherence: not reported
Run-in phase: unclear
Run-out phase: unclear
Outcomes Primary: unclear which is the primary outcome
Secondary: unclear
24-Hour sputum volume; sputum leucocyte density (per mL); sputum pathogenic density (colony-forming unit (cfu)
- mL~); sputum (sol phase) IL-la, TNF-a, and LTB4 ; pulmonary function test (FEV1, FVC)
Post hoc analysis: unclear
Notes Power calculation: Based on trial authors’ experience, daily sputum volume might vary by as much as 10% between
days in patients with stable bronchiectasis. With acceptance of a type I error of 0.05 and a type II error of 0.20 (power
0.80), study size for a randomised placebo-controlled study of 20 participants (10 in each treatment group) would
allow detection of 12% change in sputum volume
Trial registration: not reported
Conflicts of interest: not declared
Funders: CRCG grant from the University of Hong Kong
Role of the sponsors: not reported
Ethical approval: yes
Conclusions: Results of this preliminary study, which is the first controlled study on the effects of erythromycin
in chronic bronchial sepsis, show the efficacy of low-dose and moderately long-term erythromycin in steady-state
bronchiectasis. Low-dose and long-term erythromycin therapy might be a disease-modifying treatment for idiopathic
bronchiectasis. Additional studies should be performed to establish dose response, appropriate duration of therapy,
and criteria for patient selection
cfu: colony-forming unit; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HRCT: high-resolution computed
tomography; IL: interleukin; LTB: leukotriene B; TNF: tumour necrosis factor.
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D A T A A N D A N A L Y S E S
Comparison 1. Macrolide versus placebo: adults
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ≥ 1 exacerbation 3 341 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.22, 0.54]
1.1 Azithromycin 2 224 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.13, 0.40]
1.2 Erythromycin 1 117 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.34, 1.63]
2 Hospitalisation: all-cause 2 151 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.19, 1.62]
2.1 Azithromycin 2 151 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.19, 1.62]
3 Serious adverse events 3 326 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.20, 1.23]
3.1 Azithromycin 2 209 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.20, 1.34]
3.2 Erythromycin 1 117 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.07]
4 Sputum weight (g): endpoint 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Azithromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 FEV1 (% predicted): endpoint 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Azithromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 FEV1 (% predicted): change
(post bronchodilator)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Erythromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 FEV1 (L): endpoint 2 94 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.17, 0.22]
7.1 Azithromycin 1 68 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.23, 0.21]
7.2 Roxithromycin 1 26 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.27, 0.57]
8 FEV1 (L): change 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Azithromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 FVC (% predicted): endpoint 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Azithromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 FVC (L): endpoint 2 94 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.19, 0.36]
10.1 Azithromycin 1 68 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.34, 0.30]
10.2 Roxithromycin 1 26 Mean Difference (IV, Fixed, 95% CI) 0.38 [-0.16, 0.92]
11 FVC (L): change 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Azithromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 FEV1/FVC: endpoint 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Azithromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Adverse events 5 435 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.51, 1.35]
13.1 Azithromycin 3 292 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.41, 1.45]
13.2 Erythromycin 1 117 Odds Ratio (M-H, Fixed, 95% CI) 1.16 [0.51, 2.62]
13.3 Roxithromycin 1 26 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.83]
14 Azithromycin-resistant bacteria
(any)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
14.1 Azithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 6-Minute walk test: change 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 Erythromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Quality of life: endpoint 1 68 Mean Difference (IV, Fixed, 95% CI) -8.90 [-13.13, -4.67]
16.1 Azithromycin 1 68 Mean Difference (IV, Fixed, 95% CI) -8.90 [-13.13, -4.67]
17 Quality of life: change 4 305 Mean Difference (IV, Fixed, 95% CI) -2.86 [-5.67, -0.04]
17.1 Azithromycin 1 141 Mean Difference (IV, Fixed, 95% CI) -3.25 [-7.19, 0.69]
17.2 Erythromycin 1 117 Mean Difference (IV, Fixed, 95% CI) -2.60 [-7.12, 1.92]
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17.3 Roxithromycin 2 47 Mean Difference (IV, Fixed, 95% CI) -1.86 [-10.63, 6.91]
Comparison 2. Macrolide versus no intervention: adults
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ≥ 1 exacerbation 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Roxithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 QoL SGRQ: endpoint total
score
2 89 Mean Difference (IV, Fixed, 95% CI) -8.81 [-14.33, -3.28]
2.1 Roxithromycin 2 89 Mean Difference (IV, Fixed, 95% CI) -8.81 [-14.33, -3.28]
Comparison 3. Macrolide versus placebo: children
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospitalisation: all-cause 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Azithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Azithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Sputum purulence score:
endpoint
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Roxithromycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 FEV1 (% predicted): endpoint 2 65 Mean Difference (IV, Fixed, 95% CI) 1.73 [-3.32, 6.78]
4.1 Azithromycin 1 40 Mean Difference (IV, Fixed, 95% CI) 3.70 [-5.99, 13.39]
4.2 Roxithromycin 1 25 Mean Difference (IV, Fixed, 95% CI) 1.0 [-4.91, 6.91]
5 Adverse events 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Azithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Azithromycin-resistant bacteria
(any)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Azithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Azithromycin-resistant
Streptococcus pneumoniae
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Azithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Azithromycin-resistant
Staphylococcus aureus
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Azithromycin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Macrolide versus placebo: adults, Outcome 1 ≥ 1 exacerbation.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 1≥ 1 exacerbation
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Altenburg 2013 (1) 20/43 32/40 27.7 % 0.22 [ 0.08, 0.58 ]
Wong 2012 (2) 22/71 46/70 49.9 % 0.23 [ 0.12, 0.47 ]
Subtotal (95% CI) 114 110 77.6 % 0.23 [ 0.13, 0.40 ]
Total events: 42 (Macrolide), 78 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 5.06 (P < 0.00001)
2 Erythromycin
Serisier 2013 (3) 39/59 42/58 22.4 % 0.74 [ 0.34, 1.63 ]
Subtotal (95% CI) 59 58 22.4 % 0.74 [ 0.34, 1.63 ]
Total events: 39 (Macrolide), 42 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 173 168 100.0 % 0.34 [ 0.22, 0.54 ]
Total events: 81 (Macrolide), 120 (Placebo)
Heterogeneity: Chi2 = 5.65, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 4.60 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.64, df = 1 (P = 0.02), I2 =82%
0.05 0.2 1 5 20
Favours Macrolide Favours Placebo
(1) 1750 mg/week for 52 weeks
(2) 1500 mg/week for 6 months
(3) 1750 mg/week 48 weeks
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Analysis 1.2. Comparison 1 Macrolide versus placebo: adults, Outcome 2 Hospitalisation: all-cause.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 2 Hospitalisation: all-cause
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Altenburg 2013 (1) 3/43 6/40 62.1 % 0.43 [ 0.10, 1.83 ]
Lourdesamy 2014 (2) 3/33 4/35 37.9 % 0.78 [ 0.16, 3.76 ]
Total (95% CI) 76 75 100.0 % 0.56 [ 0.19, 1.62 ]
Total events: 6 (Macrolide), 10 (Placebo)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours Macrolide Favours Placebo
(1) 1750 mg/week for 52 weeks
(2) 1000 mg/week for 12 weeks
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Analysis 1.3. Comparison 1 Macrolide versus placebo: adults, Outcome 3 Serious adverse events.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 3 Serious adverse events
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 3/33 4/35 26.0 % 0.78 [ 0.16, 3.76 ]
Wong 2012 (2) 4/71 9/70 63.0 % 0.40 [ 0.12, 1.38 ]
Subtotal (95% CI) 104 105 89.0 % 0.51 [ 0.20, 1.34 ]
Total events: 7 (Macrolide), 13 (Placebo)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Erythromycin
Serisier 2013 (3) 0/59 1/58 11.0 % 0.32 [ 0.01, 8.07 ]
Subtotal (95% CI) 59 58 11.0 % 0.32 [ 0.01, 8.07 ]
Total events: 0 (Macrolide), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 163 163 100.0 % 0.49 [ 0.20, 1.23 ]
Total events: 7 (Macrolide), 14 (Placebo)
Heterogeneity: Chi2 = 0.48, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.005 0.1 1 10 200
Favours Macrolide Favours Placebo
(1) 1000 mg/week for 12 weeks
(2) 1500 mg/week for 6 months
(3) 1750 mg/week for 48 weeks
76Macrolide antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Macrolide versus placebo: adults, Outcome 4 Sputum weight (g): endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 4 Sputum weight (g): endpoint
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 33 29.9 (19.4) 35 26.2 (20.5) 3.70 [ -5.78, 13.18 ]
-50 -25 0 25 50
Favours macrolide Favours placebo
(1) Azithromycin 1000 mg/week for 12 weeks
Analysis 1.5. Comparison 1 Macrolide versus placebo: adults, Outcome 5 FEV1 (% predicted): endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 5 FEV1 (% predicted): endpoint
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 33 51.79 (18.4) 35 48.81 (20) 2.98 [ -6.15, 12.11 ]
-10 -5 0 5 10
Favours Placebo Favours Macrolide
(1) D: 1000 mg; F:1/week; ID: 3 months
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Analysis 1.6. Comparison 1 Macrolide versus placebo: adults, Outcome 6 FEV1 (% predicted): change (post
bronchodilator).
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 6 FEV1 (% predicted): change (post bronchodilator)
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Erythromycin
Serisier 2013 (1) 59 -1.6 (4.6) 58 -4 (6.6) 2.40 [ 0.34, 4.46 ]
-4 -2 0 2 4
Favours Placebo Favours Macrolide
(1) Dose: 250 mg; Frequency:2/day; Intervention duration: 12 months
Analysis 1.7. Comparison 1 Macrolide versus placebo: adults, Outcome 7 FEV1 (L): endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 7 FEV1 (L): endpoint
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 33 1.09 (0.4) 35 1.1 (0.53) 78.4 % -0.01 [ -0.23, 0.21 ]
Subtotal (95% CI) 33 35 78.4 % -0.01 [ -0.23, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 Roxithromycin
Juthong 2011 (2) 12 1.49 (0.61) 14 1.34 (0.47) 21.6 % 0.15 [ -0.27, 0.57 ]
Subtotal (95% CI) 12 14 21.6 % 0.15 [ -0.27, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
-0.5 -0.25 0 0.25 0.5
Favours Placebo Favours Macrolide
(Continued . . . )
78Macrolide antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 45 49 100.0 % 0.02 [ -0.17, 0.22 ]
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours Placebo Favours Macrolide
(1) 1000 mg/week for 3 months
(2) 2100 mg/week for 8 weeks
Analysis 1.8. Comparison 1 Macrolide versus placebo: adults, Outcome 8 FEV1 (L): change.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 8 FEV1 (L): change
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Wong 2012 (1) 71 0 (0.21) 70 -0.04 (0.21) 0.04 [ -0.03, 0.11 ]
-0.1 -0.05 0 0.05 0.1
Favours placebo Favours macrolide
(1) 1500 mg/week for 6 mths
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Analysis 1.9. Comparison 1 Macrolide versus placebo: adults, Outcome 9 FVC (% predicted): endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 9 FVC (% predicted): endpoint
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 33 58.79 (20.7) 35 57.72 (22.8) 1.07 [ -9.27, 11.41 ]
-10 -5 0 5 10
Favours Placebo Favours Macrolide
(1) 1000 mg/week for 3 months
Analysis 1.10. Comparison 1 Macrolide versus placebo: adults, Outcome 10 FVC (L): endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 10 FVC (L): endpoint
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 33 1.58 (0.63) 35 1.6 (0.7) 74.4 % -0.02 [ -0.34, 0.30 ]
Subtotal (95% CI) 33 35 74.4 % -0.02 [ -0.34, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
2 Roxithromycin
Juthong 2011 (2) 12 2.29 (0.7) 14 1.91 (0.7) 25.6 % 0.38 [ -0.16, 0.92 ]
Subtotal (95% CI) 12 14 25.6 % 0.38 [ -0.16, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 45 49 100.0 % 0.08 [ -0.19, 0.36 ]
-1 -0.5 0 0.5 1
Favours Placebo Favours Macrolide
(Continued . . . )
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(. . . Continued)
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Chi2 = 1.57, df = 1 (P = 0.21), I2 =36%
-1 -0.5 0 0.5 1
Favours Placebo Favours Macrolide
(1) 1000 mg/week for 3 months
(2) 2100 mg/week for 8 weeks
Analysis 1.11. Comparison 1 Macrolide versus placebo: adults, Outcome 11 FVC (L): change.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 11 FVC (L): change
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Wong 2012 (1) 71 -0.02 (0.26) 70 -0.1 (2.6) 0.08 [ -0.53, 0.69 ]
-1 -0.5 0 0.5 1
Favours placebo Favours macrolide
(1) 1500 mg/week for 6 mths
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Analysis 1.12. Comparison 1 Macrolide versus placebo: adults, Outcome 12 FEV1/FVC: endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 12 FEV1/FVC: endpoint
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 33 71.19 (11.9) 35 67.62 (18.9) 3.57 [ -3.89, 11.03 ]
-10 -5 0 5 10
Favours Placebo Favours Macrolide
(1) 1000 mg/week for 3 months
Analysis 1.13. Comparison 1 Macrolide versus placebo: adults, Outcome 13 Adverse events.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 13 Adverse events
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Altenburg 2013 (1) 18/43 17/40 28.4 % 0.97 [ 0.41, 2.33 ]
Lourdesamy 2014 (2) 3/33 1/35 2.4 % 3.40 [ 0.34, 34.45 ]
Wong 2012 (3) 59/71 65/70 30.7 % 0.38 [ 0.13, 1.14 ]
Subtotal (95% CI) 147 145 61.5 % 0.77 [ 0.41, 1.45 ]
Total events: 80 (Macrolide), 83 (Placebo)
Heterogeneity: Chi2 = 3.46, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.80 (P = 0.42)
2 Erythromycin
Serisier 2013 (4) 17/59 15/58 29.8 % 1.16 [ 0.51, 2.62 ]
Subtotal (95% CI) 59 58 29.8 % 1.16 [ 0.51, 2.62 ]
0.005 0.1 1 10 200
Favours Macrolide Favours Placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 17 (Macrolide), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
3 Roxithromycin
Juthong 2011 (5) 0/12 3/14 8.7 % 0.13 [ 0.01, 2.83 ]
Subtotal (95% CI) 12 14 8.7 % 0.13 [ 0.01, 2.83 ]
Total events: 0 (Macrolide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
Total (95% CI) 218 217 100.0 % 0.83 [ 0.51, 1.35 ]
Total events: 97 (Macrolide), 101 (Placebo)
Heterogeneity: Chi2 = 5.54, df = 4 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi2 = 2.07, df = 2 (P = 0.36), I2 =3%
0.005 0.1 1 10 200
Favours Macrolide Favours Placebo
(1) 1750 mg/week for 12 months
(2) 1000 mg/week for 12 weeks
(3) 1500 mg/week for 6 months
(4) 1750 mg/week for 48 weeks
(5) 2100 mg/week for 8 weeks
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Analysis 1.14. Comparison 1 Macrolide versus placebo: adults, Outcome 14 Azithromycin-resistant bacteria
(any).
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 14 Azithromycin-resistant bacteria (any)
Study or subgroup Macrolide Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Altenburg 2013 (1) 20/43 22/40 0.71 [ 0.30, 1.69 ]
0.01 0.1 1 10 100
Favours Macrolide Favours Placebo
(1) 1750 mg/week for 52 weeks
Analysis 1.15. Comparison 1 Macrolide versus placebo: adults, Outcome 15 6-Minute walk test: change.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 15 6-Minute walk test: change
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Erythromycin
Serisier 2013 (1) 59 0.1 (57.5) 58 6.4 (66.6) -6.30 [ -28.86, 16.26 ]
-100 -50 0 50 100
Favours Placebo Favours Macrolide
(1) D: 250 mg; F: 2/day; ID: 12 months
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Analysis 1.16. Comparison 1 Macrolide versus placebo: adults, Outcome 16 Quality of life: endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 16 Quality of life: endpoint
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Lourdesamy 2014 (1) 33 30.2 (8.5) 35 39.1 (9.3) 100.0 % -8.90 [ -13.13, -4.67 ]
Total (95% CI) 33 35 100.0 % -8.90 [ -13.13, -4.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.12 (P = 0.000037)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours Macrolide Favours Placebo
(1) 1000 mg/week for 12 weeks
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Analysis 1.17. Comparison 1 Macrolide versus placebo: adults, Outcome 17 Quality of life: change.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 1 Macrolide versus placebo: adults
Outcome: 17 Quality of life: change
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Wong 2012 (1) 71 -5.17 (11.93) 70 -1.92 (11.93) 51.0 % -3.25 [ -7.19, 0.69 ]
Subtotal (95% CI) 71 70 51.0 % -3.25 [ -7.19, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
2 Erythromycin
Serisier 2013 (2) 59 -3.9 (10) 58 -1.3 (14.5) 38.7 % -2.60 [ -7.12, 1.92 ]
Subtotal (95% CI) 59 58 38.7 % -2.60 [ -7.12, 1.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 Roxithromycin
Asintam 2012 (3) 11 -7.31 (17.14) 10 -6.31 (18.11) 3.5 % -1.00 [ -16.12, 14.12 ]
Juthong 2011 (4) 12 -11.2 (11.6) 14 -8.9 (16.3) 6.8 % -2.30 [ -13.07, 8.47 ]
Subtotal (95% CI) 23 24 10.3 % -1.86 [ -10.63, 6.91 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 153 152 100.0 % -2.86 [ -5.67, -0.04 ]
Heterogeneity: Chi2 = 0.12, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
-20 -10 0 10 20
Favours Macrolide Favours Placebo
(1) 1500 mg/week for 6 months
(2) 1750 mg/week for 48 weeks
(3) 2100 mg/week for 12 weeks
(4) 2100 mg/week for 8 weeks
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Analysis 2.1. Comparison 2 Macrolide versus no intervention: adults, Outcome 1 ≥ 1 exacerbation.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 2 Macrolide versus no intervention: adults
Outcome: 1≥ 1 exacerbation
Study or subgroup Macrolide No intervention Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Roxithromycin
Liu 2014 (1) 11/22 16/21 0.31 [ 0.08, 1.15 ]
0.01 0.1 1 10 100
Favours Macrolide Favours No Intervention
(1) 1050 mg/week for 6 months
Analysis 2.2. Comparison 2 Macrolide versus no intervention: adults, Outcome 2 QoL SGRQ: endpoint
total score.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 2 Macrolide versus no intervention: adults
Outcome: 2 QoL SGRQ: endpoint total score
Study or subgroup Macrolide No intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Roxithromycin
Liu 2012 24 42 (12) 22 48 (13) 58.1 % -6.00 [ -13.25, 1.25 ]
Liu 2014 (1) 22 42.7 (13.5) 21 55.4 (15) 41.9 % -12.70 [ -21.24, -4.16 ]
Total (95% CI) 46 43 100.0 % -8.81 [ -14.33, -3.28 ]
Heterogeneity: Chi2 = 1.37, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours macrolide Favours no intervention]
(1) 1050 mg/week for 6 mths
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Analysis 3.1. Comparison 3 Macrolide versus placebo: children, Outcome 1 Hospitalisation: all-cause.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 1 Hospitalisation: all-cause
Study or subgroup Macrolide Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Valery 2013 (1) 3/45 9/44 0.28 [ 0.07, 1.11 ]
0.01 0.1 1 10 100
Favours Macrolide Favours Placebo
(1) 30 mg/kg/week (600 mg max) for 24 months
Analysis 3.2. Comparison 3 Macrolide versus placebo: children, Outcome 2 Serious adverse events.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 2 Serious adverse events
Study or subgroup Macrolide Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Valery 2013 (1) 11/45 19/44 0.43 [ 0.17, 1.05 ]
0.05 0.2 1 5 20
Favours Macrolide Favours Placebo
(1) 30 mg/kg/week (600 mg max) for 24 months
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Analysis 3.3. Comparison 3 Macrolide versus placebo: children, Outcome 3 Sputum purulence score:
endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 3 Sputum purulence score: endpoint
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Roxithromycin
Koh 1997 (1) 13 1.39 (0.65) 12 2.17 (0.72) -0.78 [ -1.32, -0.24 ]
-2 -1 0 1 2
Favours Macrolide Favours Placebo
(1) D: 300 mg; F: 2 /day; ID: 3 months
Analysis 3.4. Comparison 3 Macrolide versus placebo: children, Outcome 4 FEV1 (% predicted): endpoint.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 4 FEV1 (% predicted): endpoint
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Azithromycin
Valery 2013 (1) 18 84.7 (12.9) 22 81 (18.3) 27.1 % 3.70 [ -5.99, 13.39 ]
Subtotal (95% CI) 18 22 27.1 % 3.70 [ -5.99, 13.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Roxithromycin
Koh 1997 (2) 13 86 (7) 12 85 (8) 72.9 % 1.00 [ -4.91, 6.91 ]
Subtotal (95% CI) 13 12 72.9 % 1.00 [ -4.91, 6.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
-10 -5 0 5 10
Favours Placebo Favours Macrolide
(Continued . . . )
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(. . . Continued)
Study or subgroup Macrolide Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 31 34 100.0 % 1.73 [ -3.32, 6.78 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
-10 -5 0 5 10
Favours Placebo Favours Macrolide
(1) 30 mg/kg/week (600 mg max) for 24 months
(2) 56 mg/kg/week for 12 weeks
Analysis 3.5. Comparison 3 Macrolide versus placebo: children, Outcome 5 Adverse events.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 5 Adverse events
Study or subgroup Macrolide Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Valery 2013 (1) 26/45 28/44 0.78 [ 0.33, 1.83 ]
0.1 0.2 0.5 1 2 5 10
Favours Macrolide Favours Placebo
(1) 30 mg/kg/week (600 mg max) for 24 months
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Analysis 3.6. Comparison 3 Macrolide versus placebo: children, Outcome 6 Azithromycin-resistant bacteria
(any).
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 6 Azithromycin-resistant bacteria (any)
Study or subgroup Macrolide Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Valery 2013 (1) 19/41 4/37 7.13 [ 2.13, 23.79 ]
0.01 0.1 1 10 100
Favours Macrolide Favours Placebo
(1) Dose: 30 mg/kg (600 mg max);Frequency:1/week; Intervention duration: 24 months
Analysis 3.7. Comparison 3 Macrolide versus placebo: children, Outcome 7 Azithromycin-resistant
Streptococcus pneumoniae.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 7 Azithromycin-resistant Streptococcus pneumoniae
Study or subgroup Macrolide Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Valery 2013 (1) 11/41 1/37 13.20 [ 1.61, 108.19 ]
0.01 0.1 1 10 100
Favours Macrolide Favours Placebo
(1) Dose: 30 mg/kg (600 mg max);Frequency:1/week; Intervention duration: 24 months
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Analysis 3.8. Comparison 3 Macrolide versus placebo: children, Outcome 8 Azithromycin-resistant
Staphylococcus aureus.
Review: Macrolide antibiotics for bronchiectasis
Comparison: 3 Macrolide versus placebo: children
Outcome: 8 Azithromycin-resistant Staphylococcus aureus
Study or subgroup Macrolide Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin
Valery 2013 (1) 11/41 3/37 4.16 [ 1.06, 16.32 ]
0.05 0.2 1 5 20
Favours Macrolide Favours Placebo
(1) Dose: 30 mg/kg (600 mg max);Frequency:1/week; Intervention duration: 24 months
A D D I T I O N A L T A B L E S
Table 1. Study characteristics
Study Adults/
Children
No. of par-
ticipants
Type of
macrolide
Macrolide
dose
Frequency Delivery
mode
Com-
bined
weekly
dose
Compari-
son
Duration
(months
unless
stated)
Altenburg
2013
Adults 83 Azithro-
mycin
250 mg Once daily Oral 1750 mg Placebo 12
Asintam
2012
Adults 30 Rox-
ithromycin
300 mg Once daily Oral 2100 mg Placebo 12 weeks
Cymbala
2005
Adults 12 Azithro-
mycin
500 mg 3 days per
week
Oral 1000 mg No inter-
vention
6
Diego
2013
Adults 36 Azithro-
mycin
250 mg 3 days per
week
Oral 750 mg No inter-
vention
3
Juthong
2011
Adults 26 Rox-
ithromycin
300 mg Once daily Oral 2100 mg Placebo 8 weeks
Koh 1997 Children 25 Rox-
ithromycin
4 mg/kg Twice daily Oral 56 mg/kg Placebo 12 weeks
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Table 1. Study characteristics (Continued)
Liu 2012 Adults 50 Rox-
ithromycin,
ambroxol
hydrochlo-
ride
150 mg Once daily Oral 1050 mg Ambroxol
hydrochlo-
ride (no in-
terven-
tion)
6
Liu 2014 Adults 52 Rox-
ithromycin
150 mg Once daily Oral 1050 mg No inter-
vention
6
Lourde-
samy 2014
Adults 78 Azithro-
mycin
1000 mg Weekly 1000 mg Placebo 3
Masekela
2013
Children 42 Ery-
thromycin
125 mg for
children
weighing <
15 kg and
250 mg ≥
15 kg
Daily Oral 875 mg for
children
weighing <
15 kg and
1750mg≥
15 kg
Placebo 12
Sadigov
2013
Adults 65 Azithro-
mycin
500 mg 3 days per
week
Oral 1500 mg Placebo 6
Serisier
2013
Adults 117 Ery-
thromycin
250 mg Twice daily Oral 3500 mg Placebo 11
Valery
2013
Children 89 Azithro-
mycin
30 mg/
kg up to a
maximum
of 600 mg
Once a
week
Oral 30 mg/
kg up to a
maximum
of 600 mg
Placebo 24
Wong
2012
Adults 141 Azithro-
mycin
500 mg 3 days per
week
Oral 1500 mg Placebo 6
Yalcin
2006
Children 34 Clar-
ithromycin,
supportive
therapies
15 mg/kg Daily Oral 105 mg/kg Supportive
therapies
(no inter-
vention)
3
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
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1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify randomised controlled trials (RCTs)
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter (Lefebvre 2011) are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Macrolides Explode 1 2 3
#6 macrolide*
#7 azithromycin*
#8 clarithromycin*
#9 erythromycin*
#10 roxithromycin*
#11 spiramycin*
#12 telithromycin*
#13 troleandomycin*
#14 Josamycin*
#15 Midecamycin*
#16 Oleandomycin*
#17 Solithromycin*
#18 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
#19 #4 AND #18
(Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case,
bronchiectasis)
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F E E D B A C K
Reporting error - exacerbations, 25 August 2018
Summary
We wish to point out a misreported result in the recently published Cochrane Review ’Macrolide antibiotics for bronchiectasis’. The
first sentence of the fourth paragraph of the ’Main results’ section of the abstract begins: “In children, there were no differences in
exacerbation frequency (OR 0.40, 95% CI 0.11 to 1.41)”. This was not a pre-specified outcome in the protocol for this Review (Kelly
2016). The ’Types of outcome measures’ subsection states “Where possible we will assess exacerbation and hospitalisation rates at 12
months. We will estimate annual rates in studies reporting shorter follow-up times.” The first primary outcome listed immediately
below is “Exacerbations (defined using study authors’ criteria)”. So it clear that the primary pre-specified outcome is the between-group
difference in exacerbation rates. The data that should have been extracted from Valery 2013 are reported in the first sentence of the first
complete paragraph in the right hand column of page 614: “Compared with those receiving placebo, participants in the azithromycin
group were significantly less likely to have pulmonary exacerbations (incidence rate ratio 0.50; 95% CI 0.35 to 0.71; p < 0.0001).”
So there is clear evidence that, using the Cochrane Protocol’s pre-specified primary outcome, children who received azithromycin, as
opposed to placebo, had significantly lower exacerbation rates.
The statistic reported in the abstract (OR 0.40, 95% CI 0.11 to 1.41) is extracted from the third row of Table 3 of Valery 2013. It is the
odds of a child treated with azithromycin, as opposed to a child treated with placebo, being exacerbation-free at 24 months. That is, it is
the odds of azithromycin stopping any exacerbations. This outcome was not pre-specified in the Cochrane Protocol as either a primary
or secondary outcome. Furthermore it does not make sense clinically. While, in the population of children with either bronchiectasis
or chronic suppurative lung disease, using long-term macrolides could lead to a reduction of exacerbations (through either suppression
of bacterial infections or inflammation modulation) no one would expect any intervention to completely eliminate exacerbations of
their underlying chronic illness over a 24 month period. Thus, the results of Valery 2013 are incorrectly reported, and the review could
more accurately say “In children, macrolides reduced exacerbation frequency to a greater extent than placebo (IRR 0.50, 95% CI 0.35
to 0.71)”.
Prof. Robert Ware (Griffith University), Prof. Anne Chang (Children’s Health Queensland), and Prof. Keith Grimwood (Griffith
University)
No conflicts of interest declared.
Cochrane Airways editorial team notes the feedback submitters were authors of the Valery 2013 study.
Reply
We thank Profs Ware, Chang and Grimwood for their feedback. Exacerbations were a primary outcome as specified in the protocol. We
used the each study’s definition of an exacerbation (“defined using the study authors’ criteria”) rather than trying to apply a standardised
definition of exacerbation to each study retrospectively. The “study authors’ criteria” does not refer to our choice of outcome measures
(i.e. rates, etc of those exacerbations).
We did extract the incidence rate ratio from Valery 2013 and this is reported in our original review (second sentence following
“Macrolides versus placebo: children … Exacerbations”). In response to this feedback we have revised the relevant sections of the
abstract (main results), effects of interventions and summary of findings table 3 slightly to highlight this statistic more prominently.
We believe our review is consistent with our initial protocol and that there aren’t “reporting errors”. The overall message of our review
is unchanged.
Iain Crossingham, Sally Spencer, Steve Milan and James Chalmers.
Contributors
Feedback contributors: Prof. Robert Ware (Griffith University), Prof. Anne Chang (Children’s Health Queensland), and Prof. Keith
Grimwood (Griffith University)
Author contributors: Iain Crossingham, Sally Spencer, Steve Milan and James Chalmers.
96Macrolide antibiotics for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Date Event Description
17 October 2018 Feedback has been incorporated Authors have responded to Feedback 1. They changed the emphasis slightly
around reporting of exacerbations. They also reported the incidence rate ratio,
rather than the odds of not experiencing an exacerbation over a year, in the
abstract and summary of findings table
H I S T O R Y
Protocol first published: Issue 10, 2016
Review first published: Issue 3, 2018
Date Event Description
8 October 2018 Amended Feedback added, but not incorporated.
C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to preparation of the Background section.
Lambert Felix, Nicola Relph, Stephen J Milan, and Sally Spencer contributed to the methods, results, discussion, and conclusions of
the review.
David Evans, Carol Kelly, and Lambert Felix contributed to screening searches and identifying the included studies
James Chalmers, Iain Crossingham, and Carol Kelly contributed to the methods, discussion, and conclusions sections.
D E C L A R A T I O N S O F I N T E R E S T
Sally Spencer, Carol Kelly, and Nicola Relph were named co-investigators on a study funded by Edge Hill University to develop a series
of reviews on bronchiectasis. Lambert Felix was supported by that funding. No funding was received by any other review authors for
participation in this systematic review.
David Evans provides freelance writing services to medical communication agencies.
Steve Milan: none known.
Iain Crossingham received travel and training expenses from Hamilton Medical that are not connected to the topic of this review.
James D Chalmers declares grant support from Pfizer, AstraZeneca, and GlaxoSmithKline. In addition, he is part of an innovative
medicines initiative consortium that includes Novartis and Basilea. He has participated in advisory boards for Bayer HealthCare, Chiesi,
and Raptor Pharmaceuticals. He has received fees for speaking from Napp, AstraZeneca, BI, and Pfizer. None of these conflicts of
interest are related to the work involved in this review, and these conflicts are unrelated to the topic of this review.
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S O U R C E S O F S U P P O R T
Internal sources
• Edge Hill University, UK.
Funded Lambert Felix to provide support for a series of reviews on bronchiectasis. Carol Kelly and Sally Spencer were co-applicants
on the internal funding bid.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We decided to present the results for adults and for children as separate comparisons. We also decided to present the results for different
macrolides separately.
Regarding systemic markers of infection, during the course of the review, we decided to focus specifically on C-reactive protein for
the secondary outcome on systemic markers of infection, as it is the most widely used biomarker of systemic inflammation in clinical
practice.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [adverse effects; ∗therapeutic use]; Azithromycin [adverse effects; therapeutic use]; Bronchiectasis [∗drug therapy];
Clarithromycin [adverse effects; therapeutic use]; Erythromycin [administration & dosage; therapeutic use]; Macrolides [adverse effects;
∗therapeutic use]; Randomized Controlled Trials as Topic; Roxithromycin [adverse effects; therapeutic use]
MeSH check words
Adult; Child, Preschool; Humans
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